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Cancer is a leading cause of death worldwide, accounting for around 13% of all death [1]. 
Traditional cancer therapeutics usually require careful selection of one or more intervention, 
such as surgery, radiotherapy, and chemotherapy, which have made momentous progress, but 
have ample limitations [2]. The next generation of cancer therapeutics will specifically target 
processes responsible for the growth and survival of cancer cells. Among the most promising of 
these molecularly-targeted therapeutics are short interfering RNAs (siRNAs). These siRNAs 
serve as the effectors of RNA interference, a naturally occurring and highly specific mechanism 
for regulating gene expression through sequence-specific degradation of messenger RNA. 
However, the native structure of RNA is plagued with undesirable chemical properties. For 
example, the sugar-phosphate backbone contains a negative charge which hinders its ability to 
cross the negatively charged lipid bilayer. Furthermore, the phosphodiester backbone is a 
substrate for nucleases, which catalytically cleaves the phosphate-oxygen bond, thus degrading 
the native RNA [3]. As such, there is widespread interest in chemically modifying the backbone 
of siRNAs in order to overcome some of the inherent problems with its native structure. 
There have been only two reports that have employed amide-bond linkages as phosphate 
replacements within siRNAs [4, 5]. In both of these studies, the amide bond containing monomer 
units were placed at the 3’-overhangs and not within the internal Watson-Crick region of the 
double stranded siRNA due to the limitation of standard solid-phase oligonucleotide synthesis. In 
this thesis, we proposed to utilize phosphoramidite chemistry to localize internal amide-bond 
modifications [6]. A practical synthesis of a peptide nucleic acid unit combined with an RNA 
nucleoside (PNA-RNA dimer, UaU) is reported [7]. Using this PNA-RNA dimer 
phosphoramidite allows us to control the site-specific location of the internal amide-bond 
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modification throughout the desired RNA strand. Polyacrylamide gel (PAGE) and mass 
spectrometry analysis were performed to ensure the formation of full-length modified siRNA 
molecules.  
The effects of these modifications were explored with respect to the biophysical and 
biological properties of the modified siRNAs. The techniques used in this work included 
hybridization affinity assays (melting temperature), secondary structure determination (circular 
dichroism), cell-based luciferase assays, and nuclease stability assays. Melting temperature 
experiment reveals that localizing a UaU dimer unit within the RNA oligonucleotides has an 
overall destabilizing effect, whereas UaU modifications at the 3’-overhang positions show little 
change in thermal stability. Circular dichroism experimental results illustrate that all chemically 
modified siRNAs exhibit the standard A-form helix. In cell-based luciferase assays, we utilized 
two different target sequences and our results highlight the compatibility of utilizing a neutral 
amide-bond backbone within siRNAs. Specifically, the internal amide-bond modification is 
compatible within the RNAi machinery when placed at 3’-overhang position in the sense strand 
of the double-stranded siRNA.  However, poor efficacy is observed when this unit is placed 
adjacent the Ago 2 cleavage site on the antisense strand. The nuclease stability assays reveal that 
the introduction of a PNA-RNA dimer at the 3’-end of the siRNA where the exonuclease cleaves 
the terminal nucleotide, increased markedly the resistance to serum-derived nucleases. To the 
best of our knowledge, this is the first report that involves amide-bonds as phosphate backbone 
replacements within the internal regions of siRNAs and thus opens the future possibility for 
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Chapter 1: Introduction 
1.1. Structure and Conformation of Nucleic Acids 
DNA and RNA consist of heterocyclic bases built on a sugar–phosphate backbone 
polymer (Figure 1-1). At neutral pH, the phosphates are constitutively negatively charged. DNA 
and RNA differ in two important structural aspects. In DNA, the four nitrogenous bases are 
adenine (A), guanine (G), cytosine (C), and thymine (T), while in RNA, the thymine is 
substituted by uracil (U). Secondly, the main difference between DNA and RNA is the presence 
of the 2’ hydroxyl group attached to the pentose ring in RNA. This small difference leads to very 












Figure 1-1: Primary structure of DNA and RNA. Note that RNA contains uracil instead of 




The bases of DNA and RNA are capable of hydrogen bonding to each other via canonical 
(i.e. Watson-Crick) base pairs, A-U/T and G-C to form a double helix. The phosphate moiety 
and the sugar form the backbone of the helix. Each nucleic acid strand has polarity, or sense, and 
pairing occurs with one strand lies in the 5’ to 3’ orientation and the other strand in the 3’ to 5’ 
orientation to form a double stranded duplex.  
As described in the central dogma of molecular biology, the genetic information is 
transferred from DNA to RNA to proteins (Figure 1-2). During replication, the double helical 
DNA unwinds and creates a copy of itself. The genetic information stored in double helical DNA 
is faithfully transmitted to the progeny of any cell or organism. The information contained in a 
section of DNA is transferred to messenger RNA (mRNA) by a process called transcription, and 
RNA binds to ribosomes to assemble proteins by a process called translation. In the case of 
retroviruses, such as HIV, as well as in eukaryotes, reverse transcription occurs, creating single-
stranded DNA from an RNA template. Since the 1970s, tremendous interest has been generated 
in the development of technologies that employ synthetic oligonucleotides (ONs) as therapeutics 
for manipulating gene expression in living cells. For instance, synthetic ONs can be used to 
modify gene expression and inhibit the replications of certain virus in the cells [8]. ONs 
therapeutics has been considered as a potential treatment for viral diseases and also for cancer 
which is caused by aberrant gene expression [9]. 





1.2. RNA Interference (RNAi) 
ONs are chemically synthesized short nucleic acid sequences (DNA or RNA). They can 
selectively inhibit the gene expression by interfering with the flow of genetic information in 
biological systems, resulting from their binding to the target sequence by a variety of 
mechanisms.  One of the most investigated mechanisms is the antisense pathway, in which 
complementary ONs (antisense ONs) hybridize to the mRNA strand of the targeted gene based 
on complementarity [10]. After hybridization, the gene expression of the target mRNA is 
blocked either sterically by obstructing the ribosomes, or by forming an RNA-DNA hybrid, 
which is a substrate for RNase H enzyme, thereby causing the cleavage of desired target mRNA. 
Besides antisense, there are other mechanisms that are available for selective inhibition of gene 
expression. For instance, the antigene mechanism where a single-stranded ON, also called 
triplex-forming oligonucleotides (TFOs), hybridizes to the purine or pyrimidine-rich region in 
the major groove of double-helical DNA through Hoogsteen base pairing and prevents the 
unwinding of double helical DNA necessary for transcription of the targeted region or blocks the 
binding of transcription factor complexes [11]. 
The focus of this thesis will involve using the RNA interference (RNAi) pathway, which 
has generated the most interest in recent years as a therapeutic potential. Another name for RNAi 
is post-transcriptional gene silencing (PTGS), which is a natural process in eukaryotic cells, by 
which double-stranded short interfering RNA (siRNAs) targets mRNA for cleavage in a 
sequence-specific manner [12]. It provides an innate defense mechanism against invading viruses 
and transposable elements. If siRNA is delivered to the cell, it will utilize the endogenous RNA-
induced silencing complex (RISC) and this results in potent and specific silencing of the targeted 




is that, in theory, we can design siRNAs to target virtually any gene of interest. Because of the 
potency and selectivity of RNAi, it has become the method of choice for silencing specific gene 
expression in mammalian cells. Specially, control of disease-associated genes makes RNAi an 
attractive choice for future therapeutics.  
The discovery of the RNAi mechanism occurred in a successive way. The RNAi 
phenomenon was first reported by Napoli and Jorgensen in 1990 [13]. The suppression of the 
endogenous gene by the introduction of homologous RNA sequence was later reported by 
Romano and Macino in Neurospora crassa in 1992 [14]. In 1995, Guo and Kemphues 
demonstrated the capacity of single-stranded RNAs (ssRNAs) to induce PTGS in the nematode 
Caenorhabditis elegans [15]. However, the role of double-stranded RNA (dsRNA) in gene 
silencing was not evident in the effects discovered in plants and C. elegans. Clear evidence for 
the participation of dsRNA in post transcriptional gene silencing was revealed in 1998 by Fire, 
Mello, and coworkers, who reported that an externally introduced long dsRNA could decrease 
the expression of a complementary mRNA in C. elegans [16]. Research into the therapeutic 
applications of RNAi gained momentum after the seminal discovery in 2001 by Tuschl and co-
workers that synthetic 21-nucleotide (nt) siRNAs could trigger an RNAi response in mammalian 
cells [17]. 
 
1.2.1. Mechanism of siRNA-Initiated RNAi in Humans 
Since the discovery and characterization of RNAi in C elegans [15], the broad 
mechanistic details for the pathway have been largely characterized. Unlike C. elegans, longer 
double-stranded RNAs cannot be used to initiate RNAi in mammalian cells because of the innate 




have potential immunogenicity [20]. Nonetheless, siRNAs remain the most viable candidates for 
application of RNAi as a human therapeutic approach. The development of RNAi for therapy is 
based on our understanding of small RNA biogenesis pathways. The two main types of small 
RNAs involved in gene silencing are siRNAs and microRNAs (miRNAs).  
SiRNAs are small double-stranded RNAs (dsRNAs), 20–24nt (nucleotide) in length, that 
are processed from longer dsRNAs. One strand is the ‘guide’ strand and directs silencing, with 
the other strand - the ‘passenger’ - is degraded after the ‘guide’ strand is loaded within the RISC 
complex [21, 22]. SiRNAs generally show full complementarity to their target mRNA, and 
cleavage occurs 10–12 bases from the 5’-end of the guide strand binding site [17, 23]. The most 
common method to harness the RNAi pathway for targeted gene silencing is to transfect 21-22nt 
siRNAs into cells. Another way is to use longer, 25-27nt duplexes that can be later processed by 
Dicer which is a member of the RNase III family of ribonucleases that cleaves dsRNA into 
siRNA in the cytoplasm [24]. The complex of double-stranded siRNA and Dicer is then loaded 
into the RNA-induced silencing complex (RISC) [25] which is a group of proteins, including one 
of the Argonaute (Ago) proteins, that induces target mRNA cleavage based on loaded siRNA 
[26]. Ago proteins are a highly conserved family that have been implicated in RNAi across 
several species [27]. Family members have two characteristic domains: PAZ and PIWI [28]. A 
group led by Joshua-Tor crystallized an Ago protein from the archebacterium Pyrococcus 
furiosus (PfAgo) [29]. The PIWI domain of PfAgo showed a remarkable similarity to the 
conserved secondary structure of RNase H enzymes [29]. Using the structure of PfAgo, Joshua-
Tor and colleagues modeled the structure of human Argonautes. Accordingly, the N-terminal, 
PIWI, and middle domains of Argonaute lie in a crescent to support the fourth domain, PAZ. The 




of the siRNA to bind to target mRNA. The target mRNA then sits on top of the PIWI domain, 
which causes cleavage of target mRNA. Immunoprecipitation results show that among the 
Argonaute family (Ago 1-4), Ago 2 is the enzyme responsible for cleaving the passenger strand 
siRNA as well as the target mRNA. 
The siRNA-Dicer complex recruits Ago 2 to form the RISC-loading complex (RLC) [30]. 
The RLC initiates siRNA unwinding and determines which strand is assembled into the RISC by 
preferentially binding the strand with lower thermodynamic stability at the 5’-end, which 
becomes the guide strand [31-34]. The passenger strand is cleaved by Ago 2 and departs the 
complex, facilitating assembly of RISC [21]. RISC mediates sequence-specific binding of the 
guide strand RNA to the corresponding target mRNA mainly with the 5’ seed region [35] 
(nucleotides 2–8 which is essential for the initial binding of the siRNA to most targets) of the 
siRNA [36]. The mRNA is then cleaved by Ago 2 at the centre of the oligonucleotide. RISC 
remains bound to the single-stranded siRNA and can execute several rounds of cleavage [37].  
Like siRNA, single-stranded RNA molecules, known as microRNAs, regulate gene 
expression as well as nucleic acids (ribozymes and DNAzymes) with catalytic activity against 





Figure 1-3: Diagrammatic Representation of Mechanism of siRNA-initiated RNA interference 
[38]. 
 
Today, RNAi has become a promising technique in the field of life sciences as well as in 
the biomedical science to characterize and knock-down a single gene or a collection of genes that 
are associated with the disease development. Cancer, AIDS, and hepatitis are diseases in which 
the effectiveness of RNAi has been already tested by scientists [39, 40].  
 
Rules for Selecting siRNA Sequences 
The initial selection of candidate siRNA sequences was based on complementarity of one 
strand of the double-stranded RNA to the target mRNA. Moreover, the structure of the siRNA, 
with the internal 19 nucleotides hybridized and 2-nucleotide overhangs at each 3’-end (typically 




subsequently came to light was that siRNAs must possess a 5’-PO3 rather than a 5’-OH [41], 
which is the typical terminal group for chemically synthesized siRNAs. This 5’-PO3 group is 
important for recognition of the siRNA by Dicer, because 5’-OCH3 and modified strands are 
bound far more weakly than phosphorylated strands [42, 43]. As such, modifying the passenger 
strand with a 5’-OCH3 can prevent its phosphorylation and therefore prevent incorporation into 
RISC [44]. 
 
1.2.2. Terminal Asymmetry Prediction 
Because siRNAs are double-stranded, either strand is capable of serving as the guide for 
active RISC. Thus, to maximize the activity of siRNAs, it is advantageous for one of the two 
strands of the siRNA to be loaded preferentially into RISC. The preference for loading one 
strand over the other is referred to as siRNA asymmetry. Based on early studies in Drosophila, it 
was proposed that siRNAs were asymmetric because of the difference in the hybridization free 
energy for the terminal four nucleotides on each end of the siRNA [31, 45]. The strand whose 5’-
end was located at the less stably hybridized end of the siRNA would preferentially be loaded 
into active RISC. This was confirmed using sequences with terminal mismatches to induce 
significant instability at one end of the siRNA. Subsequently, thermodynamic asymmetry was 
confirmed to be a useful predictor of siRNA function [46]. Theoretically placing a destabilizing 
unit at the 5’-end of the guide strand will improve the efficacy of siRNAs.  
In a recent study reported by a collaboration amongst various European research groups, 
several pairs of guide and passenger siRNA strands modified with 21 different modifications 
were used to generate a total of 2160 siRNA duplexes, which were studied for silencing activity 




3’-overhangs are the major factors that affect silencing activity [47]. Stabilizing the 3’-end of the 
guide strand or the 5’-end of the passenger strand by the use of chemical modification and 
destabilizing the 5’-end of the guide strand or the 3’-end of the passenger strand resulted in 
improved RNAi activity due to improved strand selection [48]. However, if the seed region is 
strongly destabilized, the corresponding weakening of the interaction between the guide strand 
and the target mRNA results in decreased silencing activity [47]. The highly stabilized duplexes 
were also shown to have decreased silencing activity [47]. It was thus suggested that 
destabilizing the 3’-end of the passenger strand is an optimal way of designing the desired 
efficient siRNAs. Certain favored 3’-overhangs in the guide strand and disfavoured 3’-overhangs 
in the passenger strand have been identified, which affect strand selection irrespective of the 
thermodynamic asymmetry of the duplex [47]. The passenger strand was found to be more 
tolerant to modifications than the guide strand. 
1.2.3. Challenges Involved in siRNA Therapeutics and Opportunities for Using Chemical 
Modifications 
Despite the promise shown, the clinical success has been disappointing. After several 
decades of research and development, so far very few nucleic acid therapeutics have been 
approved for human use. The limited success of ONs in clinics is attributed to the fact that 
unmodified ONs show unfavourable pharmacokinetic and pharmacodynamic properties. For 
instance, the natural siRNAs have a phosphodiester backbone, which is rapidly degraded by the 
nucleases in biological fluids. Moreover, they show extremely poor penetration (diffusion) 
across the cell membrane owing to their size and negative charge. Currently, the most mature 




some of the problems discussed above. Broadly speaking, chemical modifications used in 
siRNAs fall into three specific areas: backbone, sugar, and base. 
 
Improving Nuclease Resistance 
Unmodified siRNAs have a half-life of less than 15 min in serum, which makes them 
impractical for use in RNAi-based therapeutics. This is because the phosphodiester backbone is a 
substrate for nucleases, which catalytically cleaves the phosphate-oxygen bond, thus degrading 
the native RNA [3].  The most viable method to address the nuclease vulnerability of siRNAs is 
to use various chemical modifications. The backbone modifications involve alterations to the 
phosphate ester linkages in the nucleic acid (Figure 1-4. a). One of the more common 
modifications of this type is the phosphorothioate (PS) modification (Figure 1-4. b), in which 
one of the nonbridging phosphate oxygen atoms is replaced by sulfur to give a PS group [49]. 
This modification is widely used in antisense oligonucleotide therapeutics and is now being 
employed in siRNAs, as it provides improved nuclease resistance and favourable 
pharmacokinetic properties [50]. However, the PS modification has a tendency to bind 
nonspecifically to cellular membrane proteins, which can lead to toxicity [51]. 
 Another backbone modification used in siRNA is the boranophosphate modification 
(Figure 1-4. c), in which one of the non-bridging oxygen atoms of the phosphate moiety is 
replaced with a borane (BH3) group [52]. This modification is known to improve nuclease 
resistance by >300-fold relative to native siRNAs. A major drawback to the boranophosphate 
modification is that chemical methods for introducing the boron modification have not been 
optimized.  Instead of using more convenient phosphoramidite reagents to site-specifically 




enzymatically produced from the nucleoside boranotriphosphates using T7 RNA Polymerase 
[52], which lacks the site-specific control of the boron modification. 
The most widely used sugar modifications in siRNAs are the 2’ modifications of the 
sugar ring, namely 2’-OMe (Figure 1-4. d) [53], 2’-fluoro (Figure 1-4. e) [53, 54], and 2’-O-
methoxyethyl (2’-MOE) (Figure 1-4. f) [54]. Due to their ability to favor the 3’-endo sugar 
conformation, all these modifications are expected to form thermally stable A-type helical 
siRNA duplexes once they are introduced into siRNAs. Even though, conformational features 
alone do not decide the interfering activity, a RNA-like A type conformation is required for 
effective gene silencing. 
Another important 2’-modification employed in siRNAs is the 2’-fluoro-β-D-
arabinonucleotide (2’-O-FANA) (Figure 1-4. g) [55]. An siRNA duplex with a 3’-overhang in 
the guide strand and the entire passenger strand modified with FANA showed a 24-fold increase 
in serum half-life over unmodified siRNAs [55]. FANA differs from the other 2’ modifications 
because it is based on an arabinose sugar; the stereochemistry is opposite to that of a ribose 2’-
fluoro group (Figure 1-4, e). 
The locked nucleic acid (LNA) modification (Figure 1-4. h) is a specialized modification 
in which the 2’ and 4’ positions of the ribose ring are linked through a methylene bridge [56, 57].  
This linkage constrains the ribose ring, “locking” it into a conformation close to that formed by 
RNA after hybridization. The rigidity of the conformation of this modification also leads to 
better organization of the phosphodiester backbone, which enhances base stacking interactions as 
a result of stronger hybridization of the guide strand with the target strand. The LNA 
modification increases the thermal stability of RNA duplexes and prevent them from digestion 




59]. Gene silencing is sensitive to the position of the LNA nucleotides within the duplex, but 
well-placed LNA modification within the sense strand can enhance potency [59]. 
 
Figure 1-4: Chemical modifications used with siRNA in therapeutic approaches. 
 
Addressing siRNA Delivery 
Along with the rapid progress made in the design of efficient siRNAs, much effort is 
being directed at finding an appropriate delivery vehicle for siRNAs [60]. Unmodified siRNAs 




endogenous enzymes, and are unable to cross the cellular membrane due to their negative charge 
[61, 62]. However, unmodified siRNAs have been delivered in vivo using what is known as 
‘local delivery’, in which the siRNAs are administered through an injection or passed through 
the respiratory tract directly to the affected tissues [63-65]. Clearly, this approach is only 
appropriate for organs such as lungs and eyes. Localized injection of unmodified siRNAs to the 
vitreal cavity in the eye has been shown to be beneficial in wet AMD-related complications; the 
drug has entered phase III clinical trials [66]. A similar approach is being taken in which the 
epithelial cells in the lung are targeted for the treatment of respiratory syncitial virus (RSV); the 
drug is currently in phase II clinical trials (ALN-RSV01, Alnylam Pharmaceuticals). Not all cells 
of the human body, however, can be accessed through localized delivery, owing to the problem 
of the negative charge on siRNAs. In most cases, systemic delivery of siRNAs is essential. 
Systemic delivery involves intravenous injection of the siRNAs along with a delivery agent, 
which should be able to travel in the bloodstream to the desired organ or tissue without being 
degraded or taken up by non-target tissues in the process [12]. A systemically injected siRNA 
has to undergo a series of processes before it can enter the cell and produce the desired result.  
Two known approaches for systemic delivery are ‘complexation’ and ‘conjugation’ [62]. 
The complexation method involves formation of complexes of siRNAs with motifs that bind to 
their negative charges. The techniques used for this include lipids and liposomes such as stable 
nucleic acid–lipid particles (SNALP), antibody complexes, polycationic peptides known as 
peptide transduction domains (PTDs), and polycationic polymers. The conjugation approach 
involves attaching the siRNA to the delivery vehicle and has shown success in targeting cell 
types that are specific to the siRNAs [67, 68]. The conjugation approach is also useful, as the 




its desired function once the delivery vehicle is cleaved away [69]. Conjugates currently in use 
include lipophilic species such as cholesterol, as well as peptides and aptamers, which were 
reported to exhibit high biocompatibility and efficient gene silencing in vitro, but toxicity studies 
revealed problems in vivo. The field of siRNA delivery has undergone major improvements in 
recent years. New delivery methods are being tested, and some of the results are indeed very 
encouraging for addressing the issues associated with siRNA delivery. However, a perfect 
delivery vehicle that can overcome all associated hurdles has yet to be developed. Moreover, the 
viability of the existing delivery vehicles and strategies in clinical settings have yet to be 
evaluated. 
The research in RNA interference has made a lot of progress and improvement since its 
ground-breaking discovery in 1998. The improved design of siRNAs will be crucial, as the ideal 
drug should address such challenges as nuclease stability, immunostimulation, off-target effects, 
and delivery. Clearly these designs are in their nascent stage of development, and more in vivo 
studies are required to ascertain their full potential. Importantly, a majority of chemical 
modifications employed in siRNAs so far were originally devised for antisense technology. 
Although these modifications have proven useful to a certain extent, efforts to explore novel 
modifications for siRNAs are warranted, as their structural and functional requirements are 








1.3. Peptide Nucleic Acids (PNAs) 
Peptide nucleic acids (PNAs or aegPNAs) (Figure 1-5) are oligonucleotide mimics, in 
which the pyrimidine and purine bases are connected through a methylene carbonyl linker to an 
amino ethyl glycine backbone. The polyamide backbone was designed by Nielsen in 1991 to 
recognise DNA strands through Hoogsteen-like base pairing [70]. It was demonstrated that PNA 
oligomers form duplexes with complementary DNA, RNA and PNA strands following the 
Watson–Crick base pairing rules, whose structure differs from that of natural nucleic acids. The 
following properties make PNA so unique among other backbone modifications. They have the 
resistance to enzymatic degradation, and, they bind target gene with high affinity and high 
specificity [71]. Despite the fact that many synthetic oligonucleotides have been identified, very 
few of them, like PNA, can meet all of these key requirements simultaneously. It is for these 
reasons that scientists including us invest time and resources on this type of backbone 
modification. 
 





1.3.1. Important Properties of PNAs 
Resistance to nucleases and proteases 
Unlike DNA or other DNA analogues, PNAs do not contain any pentose sugar moieties 
or phosphate groups. They are not molecular species that are easily recognizable by either 
nucleases or proteases. Therefore the lifetime of these compounds is extended both in vivo and in 
vitro [72]. 
Thermal stability of PNA and its hybrid complexes  
PNAs are capable of hybridizing to complementary DNA as well as RNA obeying the 
Watson-Crick hydrogen bonding rules with an affinity greater than that of native nucleic acids 
[70, 73-76], which makes the discovery of PNAs invaluable.  This reason can be attributed to the 
intramolecular distances and the configurations of the nucleobases that are similar to those in 
natural nucleic acids. The properties of various duplexes of PNA, both pure and hybrid have 
been investigated extensively by absorption spectroscopy. Its hybrids complexes exhibit 
extraordinary thermal stability and display unique ionic strength properties. Typically, the Tm of 
a 15-mer PNA/DNA duplex is ∼70 ˚C, whereas the corresponding DNA/DNA duplex exhibits a 
Tm of ∼55 ˚C (pH 7, 100 mmol dm
-3 
NaCl). The thermal stability of a PNA–RNA duplex is even 
higher than that of a PNA–DNA duplex [77, 78]. The increased stability of PNA-DNA and 
PNA-RNA hybrids in comparison to DNA-DNA (RNA) hybrids is mainly attributed to the lack 








Stronger binding independent of salt concentration 
Another important consequence of the neutral backbone is that the change in ionic 
strength has little effect on the stability of PNA-DNA duplexes. This is in sharp contrast to the 
Tm values of DNA/DNA duplexes, which are highly dependent on ionic strength [72]. The 
neutral amide backbone also enables PNAs to hybridize to DNA molecules under low salt 
conditions where DNA hybridization is strongly inhibited, because no positive ions are necessary 
for counteracting the inter-strand repulsion that hampers duplex formation between two 
negatively charged nucleic acids. Consequently, the abundance and stability of intramolecular 
folding structures in the DNA or RNA molecules are significantly reduced, which makes the 
molecules more accessible to complementary PNAs. Furthermore, PNAs are stable across a wide 
range of temperature and pH values [80], unlike DNA which depurinates under acidic conditions.  
However, under basic conditions degradation of PNA may occur.    
Greater specificity of interaction 
PNA also shows greater specificity in binding to complementary DNA [72]. A 
PNA/DNA mismatch is more destabilizing than a mismatch in a DNA/DNA duplex. A single 
mismatch in mixed PNA/DNA 15-mers lowers Tm by 8–20 ˚C (15˚C on average). In the 
corresponding DNA/DNA duplexes a single mismatch lowers Tm by 4–16 ˚C (11˚C on average) 
[81]. 
Insolubility of PNA 
There are however a few drawbacks of PNA which complicate its direct use of PNA in 
many applications. Since PNAs do not carry any charges, they have poor water solubility 
compared to DNA. The degree of how PNA solubilize in aqueous environments is related to the 




some recent modifications have been reported, including the incorporation of positively charged 
lysine residues (carboxyl-terminal or backbone modification in place of glycine) and the 
introduction of negatively charged residues such as PNA/DNA chimeras [82]. These 
modifications of PNAs have shown improvements in solubility. PNAs have low cellular 
permeability, thus limiting its applications for antigene or antisense therapies. 
Cellular effects and delivery of PNA 
It is very important to understand the effect of PNA on intact cells and problems related 
to its delivery into the cell. The cellular uptake of PNA is very slow due to the presence of 
neutral backbone, which is still considered to be the major challenge than must overcome before 
it can be used as a therapeutic agent [83, 84]. So far, there are hardly any reports of the antisense 
activity of PNA in cell culture with the use of brute techniques to help bypass the membrane 
barrier. PNA–nucleic acid chimeras are reported to be taken up by Vero or NIH3T3 cells even at 
a relatively lower extracellular concentration (1 µM), which leaves us with the idea that a PNA–
DNA chimera may be a better antisense agent. The kinetics of uptake is similar to that observed 
for an oligonucleotide of the same sequence [85]. 
Flexibility of PNA 
Neutral PNA molecules have a tendency to self-aggregate to a degree that is dependent 
on the sequence of the oligomer [86]. This self-aggregation is due to the flexible natural of 
achiral polyamide backbone. Rigidification of the PNA backbone via conformational constrain to 
pre-organize the PNA structure will influence the orientational selectivity in complementary 





1.3.2. Application of PNAs 
Today there are four major groups of applications for this novel compound. First, it can 
be used a molecule tool in molecular biology and biotechnology [88-92]. Secondly, its role as a 
lead compound for the development of gene-targeted drugs applying antigene or antisense 
strategy [93, 94]. Third is the use of PNAs for diagnostic purposes and development of 
biosensors [95-98]. Forth, the study of basic chemistry  related to PNAs [77, 99, 100] for the 
improvement of basic architecture, e.g., for supramolecular constructs and to possibly generate a 
subsequent generation of PNA molecules [86]. 
 
Antisense properties of PNA 
Although it is not the intention to give an elaborate account of the ongoing development 
gene therapeutic drugs based on PNA oligomers, it is fair to say that PNA does possess many of 
the properties desired from an antisense reagent. It binds strongly and with excellent sequence 
specificity to complementary mRNA, it has very high biological stability, and targeting of 
specific mRNAs with PNA has been shown to inhibit translation of this mRNA. This has been 
demonstrated in several biological systems in vitro, and the introduction of various novel 
methods for improved delivery of PNA to eukaryotic cells has recently also shown good efficacy 
in cell culture ex vivo as well in a few cases in vivo [100-104]. 
1.3.3. Chemical Modification of PNAs 
The limitations of PNA as described above include: low aqueous solubility, ambiguity in 
DNA binding orientation and poor membrane permeability. In order to obtain improved 
properties for various applications with medicine, diagnostics, and molecular biology, the classic 




the modifications are (i) introduction of chirality into the achiral PNA backbone to influence the 
orientational selectivity in complementary binding, (ii) rigidification of PNA backbone via 
conformational constrain to pre-organize the PNA structure and entropically drive the duplex 
formation, (iii) introduction of cationic functional groups directly in the PNA backbone, in a side 
chain substitution or at the N or C terminus of the PNA, (iv) modulate nucleobase pairing either 
by modification of the linker or the nucleobase itself and (v) conjugation with ‘transfer’ 
molecules for effective penetration into cells [104].  
 
1.4. Project Definition 
The success of PNA as a DNA backbone mimic has inspired scientists to further utilize 
its improved properties in nucleic acid therapeutics. One strategy is to use the PNA monomers as 
a single unit and incorporate them into a DNA/RNA single strand. The resultant chimeric 
oligomers, in which both type of monomeric unit are present in a single chain, might combine 
the favourable hybridisation characteristics of PNA with the high water solubility of DNA/RNA. 
 Early in 1996, the Brown group has synthesized adenine, thymine and cytosine PNA 
monomers and used these monomers to assemble DNA chimeric oligomers [105]. PNA 
monomers have been placed at the 5’-end of the chimeric oligomers. The resultant chimeras 
hybridised specifically to complementary DNA. The chimeric oligomers formed more stable 
complexes with complementary DNA than do the equivalent DNA sequences. Uhlmann et al. 
also did one study on PNA-DNA chimeras [85]. In their study, the PNA monomer was placed 
not only at each end but also in the middle of the DNA single strand. They found that an 
insertion of a single PNA unit into a DNA single strand results in a significant drop of Tm 




destabilization was displayed, which is mostly due to a strong structural perturbation occurring at 
the PNA-DNA junction.  However, they found these DNA chimeras were more stable in human 
serum compared to the unmodified wild type. At the same time they showed improved aqueous 
solubility due to their partially negatively charged structure. Furthermore, because of their DNA 
component, they are more easily taken up by the cells. More importantly, DNA-PNA chimeras 
are recognized as substrates by various nucleic acid processing enzymes, which makes them 
capable of stimulating RNase H activity. Messere et al. have further examined the biological 
ability of the DNA-PNA chimeras in (a) interfering with reverse transcription reaction of 
eukaryotic mRNA and (b) inhibiting DNA-protein interactions [106]. They found that these 
chimeric molecules are efficient in interfering with real-time reaction and can inhibit DNA-
protein interactions, which makes them useful tool in the transcription factor decoy approach to 
alter gene expression. 
Compared to DNA, RNA is less stable due the presence of the 2’-OH attached to the 
pentose ring (Figure 1-6). These functional groups can chemically attack the adjacent 
phosphodiester bond to cleave the backbone (an intermolecular nucleophilic attack). Thus, there 
is widespread interest in chemically modifying the backbone of RNA in order to overcome some 
of the inherent problems with its native structure of RNA [107-109]. The success of DNA-PNA 







Figure 1-6: The phosphate backbone can be cleaved from an intermolecular nucleophilic attack. 
 
There have been only two reports that have employed amide-bond linkages as phosphate 
replacements within siRNAs [4, 5]. In both studies (Figure 1-7, A and B), the PNA monomer 
unit were placed at 3’-overhang regions of siRNAs due to the limitation of standard solid-phase 
oligonucleotide synthesis (reviewed in Chapter 2). In both studies, all amide-bond modified 
siRNAs showed enhanced nuclease resistance. In Messere’s study, the PNAs were conjugated to 
thymine dimers at the 3’-overhang of one or both strands of the siRNA (Figure 1-7, A). The 
siRNAs having PNA monomers at the passenger strand overhangs showed efficient gene 
silencing and also showed persistent silencing activity relative to other siRNAs tested. Similarly, 
Iwase et al. synthesized siRNAs modified with amide-linked oligonucleotides (Figure 1-7, B) at 
their 3’-overhangs. These modified siRNAs reduced the target gene expression in a similar 
manner to the unmodified siRNA in mammalian cells. Chimeras consisting of siRNA-PNA can 
therefore be used as potent RNAi tools with the passenger strand preferably modified as outlined 









Figure 1-7: Structures of different amide-bond derivatives used within siRNAs.  
 
In our study, through solid-phase RNA phosphoramidite chemistry, we were able to 
control the site-specific location of the PNA monomer by controlling its location within the 
desired RNA strand (Figure 1-7, C) [7].  We want to explore the scope of the PNA monomer in 
multiple positions especially within the internal Watson-Crick region of the double stranded 
siRNA. The effects of this modification were explored with respect to the biophysical and 
biological properties of the modified siRNAs by studying the thermodynamic stability, overall 
conformation, enzymatic stability, and biocompatibility of these backbone modified oligomers 






Chapter 2: Synthesis and Purification of Modified Nucleotides and 
Oligonucleotides 
2.1.  Introduction 
In this chapter, the synthesis of PNA-RNA dimer unit and the synthesis of chemically 
modified oligonucleotides will be explored. The dimer unit was placed within various RNA 
oligonucleotides via phosphoramidite chemistry [7]. 
2.1.1.  Synthesis of PNA-RNA Dimer Unit 
There is widespread interest in chemically modifying the backbone of RNA to improve 
its therapeutic properties, due to the presence of the 2’-hydroxy group which makes RNA more 
susceptible to the nuclease-assisted hydrolysis compared to DNA. Replacing an amide-bond with 
a phosphodiester via an amide-bond dimer unit could potentially offer favourable properties for 
siRNA or other nucleic-acid based applications. Figure 2-1 illustrates the structure of a uracil-
based PNA-RNA dimer unit that contains an aminoethyl glycine unit (UaU). 
 





 The synthesis of this PNA-RNA dimer unit was conceived based on the amide bond 
formation which is formed between two molecules when the carboxyl group (-COOH) of one 
molecule reacts with the amino group (-NH2) of the other molecule. As one half of the dimer unit, 
a PNA monomer (Figure 2-2) carrying the carboxyl group was coupled with a RNA monomer 
(Figure 2-2) which has the amino group, via amide synthesis with the assistance of coupling 
reagent EDC·HCl.  
 
Figure 2-2: Structure of PNA and RNA monomer 
 
2.1.2. Synthesis of Modified Oligonucleotides 
The synthetic oligonucleotides can be considered as the fuel which drives the engine of 
molecular biology. They can be found in nearly every technique in use today in molecular 
biology, such as DNA sequencing, PCR, real-time PCR, microarrays and site directed 
mutagenesis. In recent years, advances in oligonucleotide synthesis chemistry as well as in 
purification and quality control technologies have led to substantial increases in both quality and 
yield and to substantial decreases in cost. In addition, high throughput manufacturing of the full 
range of possible syntheses has largely expanded the range of the applications of modified 




oligonucleotides as it is practiced today with a focus on the phosphoramidite approach and the 
solid- phase approach. 
In nature, DNA or RNA is synthesized by the use of DNA/RNA polymerase for gene 
replication and transcription in the presence of suitable primers. The formation of the phosphate 
linkages in DNA/RNA is catalyzed enzymatically in a reversible reaction. That is, a 
deoxynucleotide triphosphate is added to a growing deoxynucleotide monophosphate polymer by 
a polymerase in the presence of Mg
2+
 and that the forward reaction resulted in the n+1 polymer 
and a pyrophosphate. In late 1950’s, Professor H. Gobind Khorana and his group at the 
University of Wisconsin accomplished this synthetically, which helped Khorana receive the 1968 
Nobel Prize in Physiology and Medicine [110]. By employing this technique, DNA/RNA can be 
synthesized chemically and enzymatically in several hundred base pairs in length. The 
deficiencies of this strategy which made this technique no longer popular and dominant are its 
inefficiency and high expenses. The coupling yields decreased markedly as the oligonucleotide 
length increased and complicated mixtures of by-products resulted. Each oligonucleotide 
required several months to a year or more to synthesize. They were considered so valuable at that 
time that they were kept under lock and key in the Khorana laboratory [110]. Moreover, 
modified oligonucleotides cannot be synthesized by using this technique. 
 
2.1.3. Phosphoramidite Chemistry 
In 1983 a breakthrough was achieved in oligonucleotide chemistry that made it possible 
to make synthetic modified oligonucleotides with high efficiency [111]. The new synthesis 
process was based upon the use of phosphoramidite monomers and the use of tetrazole catalyst 




laboratory, which make it feasible to produce these reagents commercially. To synthesize a 
standard phosphoramidite monomer (Figure 2-3, a), a dimethoxytrityl (DMT) protecting group 
(Figure 2-3, d) was attached to the 5’ position before reacting with 2-cyanoethyl N,N-
diisopropyl-chloro-phosphoramidite (Figure 2-3, b) which is later added onto the 3’ position, to 
avoid both 3’ and 5’-OH groups reacting with 2-cyanoethyl N,N-diisopropyl-chloro-
phosphoramidite. All subsequent internucleotide phosphate linkages are formed by coupling a 
5’-OH to 3’-OH nucleotides. DMT is chosen as a protecting group due to several factors. First, 
due to its bulky nature, DMT chloride selectively reacts with the primary 5’-hydroxyl group over 
more hindered secondary 3’-hydroxyl group. Secondly, the DMT group can be easily quantified 
and removed using a mild acid, such as trichloroacetic acid. Finally, when the detritylation 
happens, the intensity of orange colored trityl cations released from the solid-phase support can 
provide an easy way to rapidly and quantitatively monitor the solid-phase coupling reactions.                            
 
Figure 2-3: 2-cyanoethyl protected phosphoramidite reagent (a), 2-cyanoethyl N,N-diisopropyl-





2.1.4.  Solid-Phase Synthesis 
All phosphoramidite coupling cycle reactions are performed on the base of the solid-
phase support which is a controlled pore glass bead (CPG). This bead has a surface with holes 
and channels. It is in these that the protected nucleotide is attached covalently. The solid support 
is the highlight in genetic engineering. In 1962, Robert B. Merrifield at the Rockefeller Institute 
devised a scheme for the solid-phase synthesis of peptides [112]. The big advantage of it is the 
ease with which immobilized products can be separated from other reactants and by-products. 
The emergence of this approach elegantly reduced the tedious and time-consuming isolation of 
the product for the coupling reaction to a simple filtration step by covalently attaching one end of 
the product to an insoluble support. It is very important to select an optimum solid-phase support 
in oligonucleotides synthesis. The ideal support should act as an inert carrier without hindering 
coupling reactions and provide sufficient surface functionality to yield synthesis capacities of 
between 10 and 50 µmol/g (for small-scale) or 100 to 20 µmol/g (for large scale). In our lab, we 
use CPG which is widely used in small-scale synthesis and use succinic acid as the linker arm 
which is the compound used to join the surface of the support to the first nucleoside. The support 
is first succinylated and then coupled to a nucleoside. The solid-phase synthesis is performed 
automatically by using DNA synthesizers.  It only requires delivery of reagents to a reservoir 
containing the insoluble support and the subsequent elution of the unreacted reagents from the 
support using solvent washes. With appropriate computer control, many dozens of even hundreds 
of individual, repetitive steps can be programmed to run automatically, and such automation held 






2.1.5.  Phosphoramidite Coupling Cycle Chemistry 
The link to the solid support is made through the 3’ carbon and synthesis precedes 3’ to 5’ 
rather than the 5’ to 3’ synthesis used previously in enzymatic approach.  Phosphoramidite 
synthesis begins with the 3’-most nucleotide and proceeds through a series of cycles composed 
of fours steps that are repeated until the 5’-most nucleotide is attached. These steps are 





Figure 2-4: The phosphoramidite coupling cycle. (1) deprotection with acid. (2) Chain extension 
using a nucleoside-3′-O-phosphoramidite activated with tetrazole. (3) Capping (acetylation) of 




Step 1: Deprotection  
The first base, which is attached to the solid support, is at first inactive because all the 
active sites have been protected by DMT group. To couple the next base on, the DMT group 
protecting the 5’-hydroxyl group must be removed. This is done by adding an acid, 
trichloroacetic acid in dichloromethane (DCM), to the synthesis column. The 5’-OH is now the 
only reactive group on the base monomer. This ensures that the addition of the next base will 
only bind to that site. The reaction column is then washed to remove any extra acid and by-
products. The amount of the trityl cation flowing out of the synthesis column is quantified which 
indicates the coupling efficiency. This feature is built in many automated DNA synthesizers. 
 
Step 2: Activation and Coupling of Next Phosphoramidite  
After the detritylation reagent has been washed from the support, the next step is the 
activation of the next nucleoside-3’-phosphormaidite and coupling of the activated base to the 
growing oligonucleotide. The activation is achieved by adding tetrazole (Figure 2-3, c) to the 
base. Tetrazole cleaves off one of the groups protecting the phosphorus linkage. This base is then 
added to the reaction column. The active 5’-OH of the preceding base and the newly activated 




The reaction column is then washed to remove any extra tetrazole, unbound base and by-
products. 
 
Step 3: Capping 
Although the efficiency of the coupling reaction is quite high (95-99% in yield), there are 
still some unreacted molecules left.  In order to prevent these unreacted molecules to further 
participate in chain growing to form a mixture of oligonucleotide impurities, the unbound, active 
5’-OH is capped with a protective group which subsequently prohibits that strand from growing 
again. This is done by adding acetic anhydride and N-methylimidazole (NMI) to the reaction 
column. These compounds only react with the 5’-hydroxyl group. The base is capped by 
undergoing acetylation. The reaction column is then washed to remove any extra acetic 
anhydride or NMI. 
 
Step 4: Oxidation 
In step 2 the next desired base was added to the previous base, which resulted in an 
unstable phosphite linkage. To stabilize this linkage a solution of dilute iodine in water, pyridine, 
and tetrahydrofuran (THF) is added to the reaction column. The unstable phosphite linkage is 
oxidized to form a much more stable phosphate linkage. The progress of this step can be 
observed by the instantaneous disappearance of the dark iodine color on contact with phosphite 
compounds.  
At this point, if the oligonucleotide sequence is incomplete then the cycle can be repeated 
as many times as necessary until the full-length sequence has been assembled. Once the 




effectively used. This is done by incubating the chain in concentrated ammonium hydroxide 
solution at 55 ºC for overnight. All the protecting groups are now cleaved, including the 
cyanoethyl group, the heterocyclic protection groups, and the DMT group on the very last base. 
For RNA synthesis, The left 2’-O protecting groups on the ribose sugar can be later removed 
through a variety of different approaches. 
 
2.2. Experimental Procedures 
Synthesis of PNA-RNA Dimer Unit  
Unless otherwise noted, all starting materials were obtained from commercial sources and 
were used without any additional purification.  Anhydrous CH2Cl2, THF and DMF were 
purchased from Sigma-Aldrich and degassed by stirring under a dry N2 atmosphere.  Purification 
by flash column chromatography was carried out with Silicycle Siliaflash 60 (230-400 mesh) 




C NMR, and 
31
P NMR 
spectra were recorded at 400, 100, and 167 MHz, respectively, in either DMSO-d6, CDCl3 or 
CD3OD. ESI-MS spectra were recorded on a Waters Quattro Micro MS. Both HRMS and ESI Q-
TOF spectra were recorded on an Agilent Q-TOF. 
2-(tert-Butyldimethylsilyloxy)ethanamine (1): 
 
To a solution of ethanolamine (9.6 mL, 159 mmol) in 100 mL of dichloromethane was dissolved 




was added tert-butyldimethylsilyl chloride (24 g, 159 mmol) and the reaction mixure was stirred 
overnight at rt. Saturated NaHCO3 was added and the resulting mixture was partitioned.  The 
organic fractions were concentrated in vacuo to afford the title compound as a clear light yellow 
oil (26.8 g, 96%) [114]. 
 
 
Ethyl 2-((2-((tert-butyldimethylsilyl)oxy)ethyl)amino)acetate (2): 
 
To a solution of 1 (6.5 g, 37 mmol) in 100 mL of dichloromethane was added triethylamine (3.7 
g, 37 mmol), and this solution was cooled in an ice-water bath. To this solution was added ethyl 
2-bromoacetate (3.1 g, 18.5 mmol) dropwise over 30 min. This reaction mixture was stirred at rt. 
until TLC analysis indicated the complete consumption of starting material (3 h). Saturated 
NaHCO3 was added and the reaction mixture was partitioned.  The organic fraction was 
concentrated in vacuo, to afford an oil which was purified by silica gel chromatography eluting 
with a gradient of hexanes/EtOAc (7:3 to 3:7) to afford the title compound as a clear yellow oil 
(2.9 g, 71%); 
1
H NMR (500 MHz, CDCl3) δ 0.00 (s, 6H), 0.84 (s, 9H), 1.19-1.23 (t, 3H, J = 8.0 
Hz), 1.87(s, 1H), 2.65-2.68 (m, 2H), 3.37 (s, 2H), 3.64-3.68 (m, 2H), 4.10-4.15 (q, 2H, J = 8.0 
Hz); 
13
C NMR (100 MHz, CDCl3) δ -5.39, 14.2, 18.2, 18.3, 25.9, 51.0, 51.3,  60.6, 62.6, 172.2; 
ESI-HRMS (ES
+
) m/z calcd for [C12H27NO3Si + H]
+









1(2H)-yl)acetamido)acetate (3):  
 
To a solution of uracil-1-yl acetic acid[115](1.79 g, 11.5 mmol) dissolved in 100 mL anhydrous 
DMF was added compound 2 (3.0 g, 11.5 mmol) and this solution was cooled in an ice-water 
bath under N2. The acid was activated with the addition of 1-ethyl-3-(3-
diethylaminopropyl)carbodiimide  hydrochloride (EDC·HCl) (4.4 g, 22.9 mmol). The reaction 
mixture was stirred for 24 h at ambient temperature and then extracted with dichloromethane and 
the organic layer was washed with H2O and brine (x3). The organic layer was collected and 
concentrated in vacuo to afford the crude product. This crude product was purified by flash 
chromatography with a gradient of hexanes/EtOAc (7:3) to 100% EtOAc to elute the title 
compound as a white solid (3.2 g, 68%). Compound 3 is a pair of rotamers; the signals to the 
major (ma.) and minor (mi.) rotamers are designated; 
1
H NMR (400 MHz, CDCl3) δ 0.04 (s, 2H, 
mi.), 0.09 (s, 4H, ma.), 0.88 (s, 3H, mi.), 0.90 (s, 6H, ma.), 1.26 (t, 2H, J = 7.0 Hz), 1.31 (t, 1H, J 
= 7.0 Hz), 3.56 (t, 2H, J = 4.7 Hz), 3.76 (t, 0.7H, J = 5.1 Hz, mi.), 3.81 (t, 1.3H, J = 5.1 Hz, ma.), 
4.15-4.19 (m, 4H), 4.48 (s, 0.7H, mi.), 4.72 (s, 1.3H, ma.), 5.71-5.74 (m, 1H), 7.15 (d, 0.7H J = 
7.8 Hz, ma.), 7.21 (d, 0.3H, J = 7.8 Hz, mi.), 8.90 (br s, 1H); 
13
C NMR (100 MHz, CDCl3) δ -




102.2, 145.1, 145.1, 150.8, 158.9, 163.4, 167.0, 167.2, 168.6, 169.2;  ESI-HRMS (ES
+
) m/z calcd 
for [C18H31N3O6Si + H]
+







To a solution of compound 3 (1.25 g, 3.0 mmol) dissolved in 10 mL of dichloromethane was 
added TEA/3HF (0.73 g, 4.5 mmol), until TLC analysis showed the consumption of starting 
material. This reaction mixture was quenched with MeOH and the reaction was evaporated in 
vacuo to afford the crude product. The crude product was dissolved in minimal 
dichloromethane/MeOH and purified by flash column chromatography eluting with a gradient of 
10% NH4OH in MeOH (5% to 10%) in dichloromethane to afford the title compound as a white 
solid (0.71 g, 79%). Compound 4 is a mixture of slowly-exchanging rotamers. 
1
H NMR (500 
MHz, CD3OD) δ 1.24-1.32 (m, 3H), 3.53 (t, 0.5H, J = 5.1Hz, mi.), 3.58 (t, 1.5H, J = 5.1Hz, ma.), 
3.66 (t, 0.5H, J = 5.3 Hz), 3.75 (m, 1.5H), 4.17 (m, 2H), 4.38 (s, 0.5H), 4.64 (s, 0.5H), 4.86 (s, 
2H), 5.66 (d, 0.5H, J = 8.0 Hz), 5.68 (d, 0.5H, J = 8.0 Hz), 7.43-7.48 (m, 1H);  
13
C NMR (100 
MHz, CD3OD) δ 11.8, 45.7, 45.2, 46.2, 46.6, 46.8, 47.0, 49.2, 57.9, 58.3, 59.9, 99.6, 145.3, 
150.2, 164.2, 167.4, 168.5; ESI-HRMS (ES
+
) m/z calcd for [C12H17N3O6 + H]
+
: 300.1190, found 












To a solution of 4 (1.0 g, 3.3 mmol) dissolved in 10ml of dry pyridine was added 4,4'-
dimethoxytrityl chloride (2.3 g, 6.6 mmol) under N2. The reaction mixture was stirred for 24 h at 
ambient temperature and then extracted with dichloromethane and the organic layer was washed 
with H2O and brine (x3). The organic layer was collected and concentrated in vacuo to afford the 
crude product. The crude product was dissolved in minimal dichloromethane/MeOH and purified 
by flash column chromatography eluting with a gradient of MeOH (1% to 5%) in 
dichloromethane to afford the title compound as a white solid (1.3g, 66%).  Compound 5 is a pair 
of rotamers; the signals to the major (ma.) and minor (mi.) rotamers are designated; 
1
H NMR 
(500 MHz, CDCl3) δ 1.23-1.27 (m, 3H), 3.31 (m, 0.63H, mi), 3.41 (m, 1.26H, ma), 3.48-3.55 (m, 
2H), 3.79 (m, 6H), 4.32 (s, 0.5H, J = 8.2Hz), 4.45 (s, 0.5H, J = 8.2Hz), 4,72 (s, 1H), 5.62 (t, 
0.66H, J = 8.2Hz), 5.72(t, 0.33H, J = 8.2Hz), 6.85(d, 4.20H, J = 7Hz), 7.22-7.39(m, 9H), 8.73(br 
s, 1H); 
13
C NMR (100 MHz, CDCl3) δ 14.1, 47.9, 55.3, 61.4, 101.9, 113.3, 127.8, 128.1, 130.1, 
144.4, 144.9, 158.7, 163.3, 167.1, 168.5; ESI-HRMS (ES
+
) m/z calcd for [C33H35N3O8 + Na]
+
: 








1(2H)-yl)acetamido)acetic acid (6): 
 
To a solution of 5 (550 mg, 0.9 mmol) dissolved in 5 ml of MeOH was added NaOH (146 mg, 
3.6 mmol). The reaction mixture was stirred for 4 h at 60˚C. The mixture was cooled in ice-water 
bath and carefully acidified to pH~5.5 with 2N aq. NaHSO4. The precipitate was filtrated off. 
The filtrate was collected and concentrated in vacuo to afford the crude product (500mg, 96%). 
Compound 6 is a pair of rotamers; the signals to the major (ma.) and minor (mi.) rotamers are 
designated; 
1
H NMR (500 MHz, CD3OD) δ 3.35-3.36 (m, 2H), 3.51-3.53 (m, 2H), 6.03 (s, 6H), 
3.89 (s, 1H), 4.09 (s, 1H), 4.57 (s, 1.5H, ma), 4.66 (s, 0.5H, mi), 6.85-6.88 (m, 4H), 7.25-7.43 (m, 
9H);  
13
C NMR (100 MHz, CD3OD) δ 50.0, 51.60, 55.9, 60.3, 62.8, 87.8, 102.3, 114.1, 127.9, 
128.8, 129.4, 130.6, 137.5, 146.4, 152.9, 160.1, 166.9, 169.4, 169.7; ESI-HRMS (ES
+
) m/z calcd 
for [C31H31N3O8 + H]
+














To a mixture of uridine (4.0 g, 11.2 mmol), sodium azide(2.2 g, 33.6 mmol) and 
triphenylphosphine (3.82g, 14.6 mmol) in 100 ml of anhydrous DMF was added carbon 
tetrabromide(5.57 g, 16.8 mmol). The reaction mixture was stir for 12 h at rt and then 
concentrated in vacuo, to afford crude product which was purified by silica gel chromatography 
eluting with a gradient of MeOH (3% to 8%) in dichloromethane to afford the title compound as 
a white solid (2.6 g, 86%). The 
1
H proton and 
13
C NMR shifts were confirmed with the report by 





To a solution of compound 7 (2.6 g, 9.66 mmol) in 50 ml of dry DMF was added imidazole (1.64 
g, 24.15 mmol) and triisopropylsilyl chloride (3.72 g, 19.3 mmol). The reaction mixture was 
stirred for 12 h at rt and then extracted with EtOAc and the organic layer was washed with H2O 




product. The crude product was dissolved in minimal dichloromethane/MeOH and purified by 
flash column chromatography eluting with a gradient of a gradient of hexanes/EtOAc (8:2 to 4:6) 
to afford the title compound as a crystalline solid (2.55 g, 62%). Compound 8 is a pair of 
rotamers; the signals to the major (ma.) and minor (mi.) rotamers are designated; 
1
H NMR (500 
MHz, CDCl3) δ 1.05-1.08 (m, 18H), 1.09-1.16 (m, 3H), 3.63 (d, 0.33H, J = 3.5Hz, mi), 3.66 (d, 
0.66H, J = 3.5Hz, ma), 3.75 (d, 0.5H, J = 2.7Hz), 3.78 (d, 0.5H, J = 2.7Hz),  4.10-4.14 (m, 1H), 
4.50 (t, 1H, J = 5.1Hz), 5.82 (d, 1H, J = 8.2Hz), 5.88 (d, 1H, J = 5.1Hz),7.47 (d, 1H, J = 8.2Hz); 
13
C NMR (100 MHz, CDCl3) δ 12.1, 17.8, 52.3, 71.2, 74.7, 82.6, 90.1, 103.3, 140.3, 150.1, 162.7; 
ESI-HRMS (ES
+
) m/z calcd for [C18H31N5O5Si + H]
+








To a solution of 8 (2.15 g, 5.06 mmol) in 200 ml of THF was added triphenylphosphine (4.44 g, 
15.2 mmol) and H2O (4.0 g, 0.222 mol). The reaction mixture was stirred for 12 h at rt and then 
concentrated in vacuo to afford the crude product. The crude product was dissolved in minimal 




8% to 10% (10% NH4OH in MeOH) to afford the title compound as a white solid (1.8 g, 89%). 
Compound 9 is a pair of rotamers; the signals to the major (ma.) and minor (mi.) rotamers are 
designated; 
1
H NMR (400 MHz, DMSO-d6) δ 0.97-1.14 (m, 21H), 2.50 (p, 1H, J1 = 3.7Hz, J2 = 
1.7Hz), 2.74-2.76 (m, 2H), 3.79-3.82 (td, 1H, J1 = 4.8Hz, J2 = 2.5Hz),  4.13-4.16 (m, 1H), 4.20-
4.22 (dd, 1H, J1 = 5.1Hz, J2 = 2.3Hz),  5.22 (br, 1H), 5.64 (d, 1H, J = 7.8Hz), 5.80 (d, 1H, J = 
6.6Hz), 7.88 (d, 1H, J = 8.2Hz), );
 13
C NMR (100 MHz, DMSO-d6) δ 11.7, 17.9, 43.4, 72.4, 72.7, 
86.7, 87.3, 102.0, 141.4, 150.9, 163.0; ESI-HRMS (ES
+
) m/z calcd for [C18H33N3O5Si + H]
+
: 









To a mixture of compound 6 (100 mg, 0.18 mmol) and 9 (58 mg, 0.15 mmol) in 6 ml of 
anhydrous DMF under N2 was added 1-ethyl-3-(3-diethylaminopropyl)carbodiimide  




stirred for 24 h at ambient temperature and then extracted with dichloromethane and the organic 
layer was washed with H2O and brine (x3). The organic layer was collected and concentrated in 
vacuo to afford the crude product. This crude product was purified by flash chromatography with 
a gradient of MeOH (2% to 6%) in dichloromethane to afford the title compound as a white solid 
(54.7 mg, 40%). 
1
H NMR (500 MHz, CDCl3) δ 1.00-1.15 (m, 21H), 3.20-3.61 (m, 6H), 3.79-
3.85 (m, 8H), 3.98-4.09 (m, 2H), 4.23-4.34 (m, 1H), 4.49 (s, 1H), 4.69-4.99 (m, 2H), 5.21 (d, 1H, 
J = 5.5Hz), 5.51-5.55 (m, 1H), 5.67-5.74 (m, 1H), 6.48-6.55 (m, 1H), 6.82-6.87 (m, 4H), 7.10-
7.38 (m, 9H); 
13
C NMR (100 MHz, CD3OD) δ 11.0, 13.5, 18.4, 18.7, 42.1, 47.3, 55.9, 62.7, 72.6, 
74.3, 75.9, 84.3, 88.7, 92.7, 102.3, 114.5, 128.0, 128.2, 128.7, 129.1, 129.5, 130.6, 131.5, 137.2, 
143.9, 144.2, 146.3, 147.8, 160.4, 170.0, 171.3; ESI-HRMS (ES
+
) m/z calcd for [C49H62N6O12Si 
+ Na]
+



















To a solution of compound 10 (83 mg, 0.104 mmol) dissolved in 5 mL of anhydrous 
dichloromethane under N2 was added N,N-diisopropylethylamine (0.67 mg, 0.52 mmol) and 2-
cyanoethyl N,N-diisopropyl-chloro-phosphoramidite (49.2 mg, 0.208 mmol). The reaction 
mixture was then stirred for 4 h under N2. This reaction mixture was dried down in vacuo to 
afford the crude product. The crude product was then re-dissolved in minimal dichloromethane 
with 2% triethylamine and purified by flash column chromatography eluting with a gradient of 
acetone/hexane (1:1) to (2:1) with 2% triethylamine to afford the title compound as a white solid 
(62 mg, 59%). 
1
H NMR (500 MHz, CDCl3) δ 0.97-1.27 (m, 33H), 2.55-2.71 (m, 4H), 3.31-3.68 
(m, 6H), 3.81-4.01 (m, 6H), 4.11-4.30 (m, 2H),4.49-4.71 (m, 1H), 4.75-5.03 (m, 1H), 5.49-5.75 
(m, 1H), 6.85 (d, 4H, J = 9Hz), 7.21-7.36 (m, 9H), 8.26, (d, 2H, J = 8.2Hz); 
13
C NMR (100 MHz, 
CDCl3) δ 12.4, 18.0, 23.4, 24.6, 26.3, 29.2, 32.1, 43.2, 46.0, 47.9, 48.9, 53.8, 55.3, 57.7, 69.5, 
73.0, 84.1, 84.6, 86.5, 87.6, 88.5, 102.4, 113.1, 113.4, 117.7, 127.3, 128.0, 128.1, 130.1, 135.0, 
144.0, 144.9, 150.5, 151.5, 158.8, 160.1, 163.3, 167.8, 168.3; 
31




149.7, 150.9; ESI-HRMS (ES
+
) m/z calcd for [C58H79N8O13PSi + Na]
+
: 1177.5166, found 
1177.5169 [M + Na]
+
.  
Synthesis of Natural or Modified Oligonucleotides  
All standard β-cyanoethyl 2’-O-TBS protected RNA phosphoramidites, reagents, and solid 
supports were purchased from Chemgenes Corporation and Glen Research. Sequences such as 
the wild-type sense and 5’-phosphorylated antisense strands were purchased and purified from 
Integrated DNA Technologies (IDT). All UaU-modified oligonucleotides were synthesized on an 
Applied Biosystems 394 DNA/RNA synthesizer using 1.0 µM or 0.2 µM cycles with 16 min 
coupling times for standard phosphoramidites. All phosphoramidites were dissolved in 
anhydrous acetonitrile to a concentration of 0.15 M.  We observed an average coupling 
efficiency of >98% with the use of the UaU phosphoramidite as monitored by trityl cation 
absorbance.  Sequences containing 3’ modifications were synthesized on 1.0 µM Universal III 
solid supports, while all other sequences were synthesized on 0.2 µM or 1.0 µM dT solid 
supports (Glen Research). Antisense sequences were chemically phosphorylated on the 5’ end 
using 2-[2-(4,4'-Dimethoxytrityloxy)ethylsulfonyl]ethyl-(2-cyanoethyl)-(N,N-diisopropyl)-
phosphoramidite (Glen Research). Cleavage of oligonucleotides from their solid supports were 
performed through on-column exposure to 1.5 mL of EMAM (methylamine 40 % wt. in H2O and 
methylamine 33 % wt. in ethanol, 1:1 (Sigma-Aldrich)) for 1 hr at rt., followed by incubation in 
EMAM overnight to deprotect the bases. After drying down the EMAM, the samples were 
resuspended in a solution of 3 HF / TEA (150 µL) and incubated at 65 ᵒC for 48 hr in order to 
remove the 2’-O-TBS and 2’-O-TIPS groups. Crude oligonucleotides were precipitated in EtOH 
and desalted through Millipore Amicon Ultra 3000 MW cellulose centrifugal filters. 




desalting through centrifugal filters. Equimolar amounts of complimentary RNAs were annealed 
at 90 ᵒC for 2 min in a binding buffer (75 mM KCl, 50 mM Tris-HCl, 3 mM MgCl2, pH 8.3) and 
this solution was cooled slowly to rt to generate siRNAs. 
ESI Q-TOF Measurements. All single-stranded RNAs were gradient eluted through a Zorbax 
Extend C18 HPLC column with a MeOH/H2O (5 : 95) solution containing 200 mM 
hexafluoroisopropyl alcohol and 8.1 mM triethylamine, and finally with 70% MeOH. The eluted 
RNAs were subjected to ESI-MS (ES
-
), producing raw spectra of multiply-charged anions and 
through resolved isotope deconvolution, the molecular weights of the resultant neutral 
oligonucleotides were confirmed for all the RNAs. This service was performed by Dr. Jim 
Windak at the University of Michigan in Ann Arbor, Michigan. 
 
2.3. Results and Discussion 
To synthesize a PNA unit (Scheme 1), we started with protecting the hydroxyl group of 
commercially available ethanolamine with tert-butyldimethylsilyl (TBS) chloride to afford TBS-
protected ethanolamine in 96% yield. TBS is one of the most common silyl ethers which are 
usually used as protecting groups for alcohols in organic synthesis. It can be easily removed with 
acids and fluorides later. The next step is to selectively monoalkylate 1 with the alkylating agent 
ethylbromoacetate under basic conditions to afford compound 2 in 71% yield. In order to avoid 
dialkylation of 1, only 0.5 equivalents of ethylbromoacetate was added dropwise and the reaction 
progress was closely monitored by TLC analysis. The crude product was immediately purified 
by silica gel chromatography. With compound 2, amide-bond formation with uracil-1-yl acetic 




compound 3 in 68% yield. EDC is a water soluble carbodiimide which is used as a carboxyl 
activating agent for the coupling of primary amines to yield amide bonds [117]. Compared to 
other coupling reagents such as dicyclohexylcarbodiimide (DCC) (Figure 2-5, b), 1-hydroxy-
1H-benzotriazole (HOBt) (Figure 2-5, c) and O-Benzotriazole-N,N,N',N'-tetramethyl-uronium-
hexafluoro-phosphate (HBTU) (Figure 2-5, d), the by-product of EDC assisted amide bond 
formation is water soluble which can be easily removed in aqueous work-up.  
 
Figure 2-5: Coupling reagents for amide bond formation  
The next step is the removal of TBS protecting group in the presence of 3HF-TEA to 
yield monoalcohol 4. This monoalcohol was then protected with 4,4'-dimethoxytrityl (DMT) 
chloride to afford the DMT-protected 5 in 66% yield. As described in the introduction, the DMT 
protecting group is needed for the standard solid-phase DNA/RNA synthesis. Compound 5 was 
readily saponified with NaOH and then acidified with KHSO4 buffer to afford the final acetic 
acid 6 in 96% yield. Due to the presence of DMT group which is acid labile, during the last step 
of acidification, the pH value was strictly controlled in the range of 5.5-6 in order to prevent the 






Scheme 1: Synthesis of a 4,4'-dimethoxytrityl-protected uracil acetic acid derivative. 
 
To synthesize the RNA monomer (Scheme 2), 5'-azidouridine was synthesized from 
commercially available uridine in the presence of NaN3, PPh3, and CBr4 [118]. In order to 
protect 2'-O position of compound 7, triisopropylsilyl (TIPS) chloride was utilized with 
imidazole to afford compound 8 in 62% yield. In this step, TBS chloride was originally used like 
the case of the first protection of hydroxyl group in PNA monomer. We later found that TBS 
group has a tendency to constantly migrate from 2'-O and 3'-O position, thus resulting in the 
formation of a mixture of two TBS protected regioisomers. This was confirmed by the results 
from both TLC and 
1
HNMR. The isolation of the 2'-O TBS protected product was unsuccessful. 
In order to avoid this problem, TIPS group as another silyl ether was chosen for the 2'-O 
protection of compound 7. The greater bulkiness of TIPS group makes it more difficult to 
migrate from 2'-O and 3'-O position, which resulted in the formation of more stable TIPS 
protected products (2'-O and 3'-O protected). Using column chromatography, the isolation the 2'-




by 2D COSY NMR analysis. A characteristic doublet of doublet H2' chemical shift occurred at 
4.50 ppm and the H3' and H4' proton shifts were indistinguishable. Reduction of the azido sugar 
8 was achieved using standard Staudinger conditions in THF to afford 9 in 89% yield [118]. The 
characteristic H2' chemical shift of 9 appeared as a doublet of doublet at 4.21 ppm. Overall, this 
RNA building block was synthesized in 49% yield over three steps. 
 
Scheme 2: Synthesis of 5'-amino-2'-O-triisopropylsilyluridine 
 
With both compound 6 and 9 available, we amide-bond coupled these two monomers 
together in the presence of EDC in anhydrous DMF to afford the dimer UaU 10 in 40% yield. 
Finally, compound 10 was subsequently phosphorylated with 2-cyano-N,N - 
diisopropylchlorophosphoramidite to yield compound 11 in 60% yield (Scheme 3). The 
31
P 
NMR for this compound showed two phosphorus peak signals due to the diasteromeric nature of 
the 
31
P atom for the respective phosphoramidite, thus, indicating a single isomeric form for the 
phosphoramidite. In this step, due to the fact that water can easily catalyze the conversion of the 
phosphoramidite to the phosphonate, all glassware was oven-dried; all reagents were either 
distilled or vacuum dried; anhydrous solvent was used in order to eliminate the presence of 




stored in the freezer under vacuum until it was ready for the solid-phase DNA/RNA chemistry to 
synthesize RNA molecules that bear this UaU  dimer modification.  
 
Scheme 3: Synthesis of UaU phosphoramidite 11 
 
 All natural or unmodified oligonucleotides were synthesized on an Applied Biosystems 
394 DNA/RNA synthesizer. All of the DNA synthesis reagents have an impact on good quality 
DNA synthesis, as are all the steps in the synthesis cycle – coupling, capping, oxidation and 
detritylation. Fundamental to the successful synthesis of longer oligonucleotides is the need to 
maintain as high a coupling efficiency as possible. An average coupling efficiency of 98% would 
theoretically yield 68% full-length product for a 20mer. Therefore, it is imperative to maintain 
high coupling efficiency throughout the synthesis. One of the main obstacles to this is the 
presence of moisture. The most simple and effective first measures to increase coupling 
efficiency are to use anhydrous acetonitrile (ACN) to dissolve all the phosphoramidites, and to 




the synthesizer is less than 2 weeks. In addition, the RNA/DNA synthesizer has to be operated 
under N2 atmosphere.  
With all full length oligonucleotides assembled, the cleavage of oligonucleotides from 
their solid supports and deprotection of all the bases were performed through the treatment in 
EMAM (methylamine 40% wt. in H2O and methylamine 33% wt. in ethanol, 1:1). The silyl 
protecting groups (TBS and TIPS groups) were deprotected by the treatment in 3HF-TEA. Due 
to the presence of TIPS groups which is highly stable, extra deprotection time (48 hours 
incubation) was needed.   After the cleavage from the solid supports and the deprotection of all 
the protecting groups, all oligonucleotides were PAGE gel purified including the following steps: 
1) pre-electrophoresis, 2) sample electrophoresis, 3) band excision from the 20% denatured gel, 3) 
overnight elution from the gel slice into buffer, 4) purification to remove all acrylamide out of 
the final product, 5) ethanol precipitation, 6) desalting through centrifugal filters, and 7) 
quantification by UV spectrometer. The overall yield of each oligonucleotide after the gel 
purification was usually under 20%. The molecular weights of the RNA oligonucleotides were 
confirmed by ESI Q-TOF analysis recorded on an Agilent Q-TOF. Table 2-1 illustrated the 











Table 2-1: Predicted and recorded masses for UaU modified sense and antisense RNAs. ESI Q-
TOF recorded in negative electrospray mode after HPLC elution using two mobile phases; 
MeOH/H2O (5:95) with 200 mM hexafluoroisopropyl alcohol and 8.1 mM triethylamine; and 70% 
MeOH. 







pGL3 RNA 1 5'- CUaUACGCUGAGUACUUCGAtt -3' 6549.95 6549.99 
pGL3 RNA 2 5'- CUUACGCUGAGUACUUCGAUaU -3' 6553.91 6553.94 
pGL3 RNA 3 5'- CUUACGCUGAGUACUaUCGAtt -3' 6549.95 6549.93 
pGL3 RNA 4 5'- CUUACGCUGAGUACUaUCGAUaU -3' 6499.97 6500.01 
pGL3 RNA 5 5’-ph-UCGAAGUACUCAGCGUAAGUaU-3’ 6719.94 6719.97 
pGL2 RNA 6 5’-ph-UCGAAGUAUaUCCGCGUACGtt-3’ 6668.94 6668.94 
pGL2 RNA 7 5’-ph-UCGAAGUAUUCCGCGUACGUaU-3’ 6672.90 6672.93 
pGL2 RNA 8 5'-CGUACGCGGAAUACUUCGAUaU-3' 6615.96 6615.96 
pGL2 RNA 9 5'-CGUACGCGGAAUACUaUCGAtt-3' 6612.02 6612.03 
 
 
2.4. Chapter Summary 
 The work that has been presented in chapter 2 represents studies on the synthesis of 
PNA-RNA dimer unit and RNAs that contain such UaU dimer unit. The use of siRNAs which 
were made from the RNAs produced in this chapter is presented in the next several chapters in 
order to elucidate the effect of the modifications on the hybridization affinity, overall 




Chapter 3: Biophysical Properties of Modified siRNAs Containing Internal 
Amide-Bond Linkages 
3.1.  Background Overview 
 It has been well established that the structure of nucleic acids plays a significant role in 
the efficacy of RNA therapeutics [34, 119]. The proper secondary structure is required for the 
antisense strand of siRNA to be loaded with the RISC complex, which is a programmable 
endonuclease [120]. Therefore, the secondary structure of siRNA is a major determinant in the 
success of gene silencing using siRNA.  
Two biophysical parameters of modified siRNA were studied in this chapter: melting 
temperature and circular dichroism. The melting temperature (Tm) of a double stranded nucleic 
acid can be used to characterize the affinity and the specificity of siRNA for its complementary 
target. Upon target recognition and binding, the siRNA/mRNA duplex is presumed to form a 
helix. The most important factors in the formation of a helix are the affinity and specificity that 
an siRNA has for its complement. Therefore, determination of the Tm of modified duplexes is a 
good way to determine the effect of the modification upon secondary structure. 
It has been shown that for the RISC mechanism to function properly, the siRNA guide 
strand must form an A-form helix with the target mRNA [121-123]. Therefore, the type of helix 
that formed between modified siRNAs and their complements were also studied in this chapter in 
order to determine the effect of the modification on the type of helix that formed. Circular 




Overall, the work presented in this chapter gives a comprehensive and systemic analysis 
of the effects of the internal amide bond modification on the secondary structure and duplex 
stability of siRNA.  
 
3.2. Thermal stability of modified RNA duplexes 
3.2.1. Introduction 
Two types of base-base interactions occur in the double helix: hydrogen bonding of the 
bases that occurs within the plane of the bases (Figure 3-1), and base stacking that occurs 
perpendicular to the plane of the bases. 
 
Figure 3-1: Two types of base interactions stabilize the double helix. Base pairing occurs in the 
plane of the bases and base stacking occurs perpendicular to the plane of the bases. 
 
 Helices are stabilized by base stacking and hydrogen bonding. As such, the measurement 
of the melting temperature (Tm) gives insight to the stability of the duplex [124]. Base stacking 




nm; consequently monitoring the UV spectrum is one way to measure the secondary structure of 
oligonucleotides. Increasing the temperature of a solution of oligonucleotides will cause a 
subsequent increase in the UV absorption as the duplex is denatured into separate single strands; 
this effect is known as hyperchromicity (Figure 3-2). The thermal denaturation of double-
stranded RNA is progressive and the concerted melting of the whole structure occurs at a well-
defined temperature, corresponding to the mid-point of a smooth transition. This temperature is 
known as the melting temperature (Tm). 
 
Figure 3-2: Hyperchromicity property of duplex oligonucleotides. Denatured, single stranded 
oligonucleotides have an increased UV absorbance as opposed to native, double stranded 
oligonucleotides. Native DNA becomes denatured as temperature is increased, and renatured as 





Figure 3-3:  A typical UV melting curve 
The example in Figure 3-3 shows a melting curve (UV absorption as a function of 
temperature). Slow heating of double-stranded RNA causes the unwinding of the ordered helical 
structure into the two single-stranded constituents. This can be seen as a sigmoidal curve of 
increasing UV absorption. The mid-point, corresponding to the precise Tm of the duplex, is 
indicated. 
 The trend of stability of oligonucleotides duplexes has shown that RNA:RNA duplexes 
are the most stable, then RNA:DNA duplexes, followed by DNA:DNA [125]. This is because the 
A from helix in RNA stacks neighboring bases in a more stable lattice. In addition, chain length 
and GC/AT ratio can affect the duplex stability. An increase in either of these variables will 
increase the Tm [124]. It has been shown that chemical modification can affect the thermal 
stability of the RNA:RNA duplex that is formed between the siRNA and its complement [126]. 
 Previous work from Iwase et al. involved placing dimer or a trimer of an amide-linked 
oligouridine derivative at the 3’-overhang regions of siRNAs.  Their data suggested that the 
amide-linked RNA segment increase the thermodynamic stability of the siRNA [5]. Messere and 




overhanging tract of PNA. The thermodynamic stability results have shown that the presence of 
a PNA dimer caused a destabilization effect on the chimeric siRNA [4] due to the fact that this 
overhang modification disrupted the overall base stacking interactions. On the other hand, work 
by Uhlmann  et al. in which the PNA monomer was placed on the 3’-overhangs and the internal 
region of DNA single strand, has shown that by introducing a single PNA unit into a DNA 
resulted in a significant drop of Tm [85]. This destabilization effect is mostly due to a strong 
structural perturbation occurs at the PNA-DNA junction when placed in the internal region of 
RNA single strand. In this section, the effect of the insertion of our PNA-RNA dimer unit into an 
RNA duplex on thermal stability will be investigated.  
 
3.2.2. Experimental Procedures 
The RNAs that were used in this chapter were all synthesized by solid-phase chemistry 
and PAGE gel purified. Equimolar amounts of each RNA strand (2.4 nmol) were annealed to 
their compliment in 400 µL of a sodium phosphate buffer (90 mM NaCl, 10 mM Na2HPO4, 1 
mM EDTA, pH 7) at 90 °C for 2 min and this solution was cooled slowly to rt. Melting 
temperatures (Tm) spectroscopy was performed on a Jasco J-815 CD equipped with temperature 
control. Tms were measured in the sodium phosphate buffer at 260 nm with a temperature range 
of 10 to 95 °C. The temperature was increased at a rate of 0.5 °C / min while absorbance was 
measured at the end of each 0.5 °C increment. Absorbance readings were automatically adjusted 
against the baseline absorbance of the sodium phosphate buffer. After averaging the range of 
absorbance values obtained from three independent experiments for each siRNA, Tms were 




the Tm hyperchromicity method, the software scans the melting curve to determine the 
temperature at which 50% of the duplex has dissociated.  
Analysis of melting profiles 
Consider a solution containing equal quantities of complementary single stranded RNA 
(ssRNA) A and B. Complementary ssRNA associate to form double stranded RNA (dsRNA) 
A·B. The reaction is governed by the equation: 
        
The concentration of the reaction products are related by the equilibrium constant:      
[   ]
[ ][ ] 
, 
the value of Keq is a function of temperature. We can equate the fundamental definition of the 
standard free energy change with its relationship to the equilibrium constant in solution. 
              
                                                                                   
Where     is the standard change in free energy 
                is the standard enthalpy change 
                is the standard entropy change 
            T is the temperature 
            R is the gas constant 
Solving for Keq: 
        
   
 
 
   
  
  
Let Css be the concentration of single strand RNA (Css = [A] = [B]) and Cds be the concentration 
of double strand RNA (Cds = [A·B]). CT is the total concentration of RNA strands (CT = 2Css + 
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Solving for Keq in terms of α and CT: 
     
   
    
  
     
[         ] 
  
  
       
  
Substituting for Keq from         
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Taking the log of both sides and solving for T: 
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From this equation, we know that temperature is a function of dsRNA fraction for a given total 
RNA strand and RNA identity (ΔHº and ΔSº). ΔHº and ΔSº values can be estimated from slopes 
and intercepts of fitted straight lines of lnKeq versus 1/T plots. 
 
3.2.3. Results and Discussion 
In order for gene silencing to occur through the RNAi pathway, the siRNA guide strand 
must recognize and bind to its target molecule in a sequence-specific manner. Therefore, the 
thermal stability of the duplex, and the information that it conveys about the structure of the 
duplex, must be studied for each sequence and modification. The uracil RNA duplexes were 
formed by the annealing of the uracil and adenine RNA 18mer strands.  The two sets of siRNA 
duplexes (pGL2 & pGL3) were formed by the annealing of the sense and antisense RNA 21mer 




specifically target reporter genes coding for two variants of firefly (Photinus pyralis, GL2 and 
GL3) luciferases which are widely used as reporters for studying gene regulation and function 
[128, 129]. There are differences in the coding sequence from each reporter gene which allows 
us to use two different parent siRNAs. Table 3-1 shows two parent siRNA duplexes that target 
pGL2 and pGL3.  
 
Table 3-1: The parent siRNA duplexes that target pGL2 and pGL3.  These siRNA duplexes only 









       
       5'-CGUACGCGGAAUACUUCGAtt-3' 
     3'-ttGCAUGCGCCUUAUGAAGCU-5' 
 
      5'- CUUACGCUGAGUACUUCGAtt -3' 




Analyses of the melting curves were performed as described in the experimental 












Table 3-2: Melting temperature (Tm ) data of RNAs complemented to rA18. 
RNA RNA duplex Tm (⁰C) ∆Tm (⁰C) 
wt RNA 
           5'-UUUUUUUUUUUUUUUUUU-3' 
           3'-AAAAAAAAAAAAAAAAA-5' 
31.4 0 
a 
           5'-UaUUUUUUUUUUUUUUUUU-3' 
           3'-AAAAAAAAAAAAAAAAA-5' 
25.7 -5.7 
b 
           5'-UUUUUUUUUUUUUUUUUaU-3' 
           3'-AAAAAAAAAAAAAAAAA-5' 
25.9 -5.5 
c 
           5'-UUUUUUUUUaUUUUUUUUU-3' 




As illustrated in Table 3-2, localizing a UaU dimer unit within the RNA oligonucleotide 
has a destabilizing effect when complemented to rA18. When the UaU dimer unit is located on 
either the 3'-end or the 5'-end, a decrease of approximately 5.5 °C is observed. When the UaU 
dimer is located internally, a larger loss in melting temperature of 8.5 °C is observed. These 















































       
    5'-CGUACGCGGAAUACUUCGAtt-3' 
3'-ttGCAUGCGCCUUAUGAAGCU-5' 
 






    5'-CGUACGCGGAAUACUaUCGAtt-3' 
3'-ttGCAUGCGCCUaUAUGAAGCU-5' 
 
        5'-CGUACGCGGAAUACUUCGAUaU-3' 
3'-ttGCAUGCGCCUUAUGAAGCU-5' 
 
             5'-CGUACGCGGAAUACUUCGAUaU-3' 
3'-UaUGCAUGCGCCUUAUGAAGCU-5' 
 
       5'-CGUACGCGGAAUACUUCGAtt-3' 
3'-UaUGCAUGCGCCUUAUGAAGCU-5' 
 
  5'-CGUACGCGGAAUACUUCGAtt-3' 
3'-ttGCAUGCGCCUaUAUGAAGCU-5' 
 


























































Table 3-3 highlights the Tm data for the siRNAs that target pGL2.  SiRNA 1 contains an 
internal UaU modification close to the 3’-end of the sense strand and a thermal decrease of ca. 
6.5 ºC is observed relative to wild-type. When two internal modifications are present (siRNA 3), 
the largest destabilization effect is observed (ca. 10 ºC), which is mostly due to a strong 
structural perturbation occurs at the PNA-RNA junction. On the other hand, modifications 




stability. This is potentially due to the fact that the base stacking of the duplex remains intact 
when the UaU modification is placed at the 3’-overhangs. Both siRNA 7 and 8 have internal UaU 
modification in the antisense. Although siRNA 8 contains an extra modification on the 3’-
overhang of the sense strand which has shown to have little effect on the duplex stability, it has 
similar thermal stability when compared to siRNA 7. Same case can be observed when siRNA 1 
is compared to siRNA 2 which also has an extra modification on the 3’-overhang of the antisense 
strand. These Tm changes are consistent with other similar studies involving PNA-DNA hybrids 
[130].  In general, internal amide-bond modifications display a degree of thermal destabilization; 






















































    5'-CUUACGCUGAGUACUUCGAtt-3' 
3'-ttGAAUGCGACUCAUGAAGCU-5' 
 
     5'-CUaUACGCUGAGUACUUCGAtt-3' 
3'-ttGAAUGCGACUCAUGAAGCU-5' 
 
       5'-CUaUACGCUGAGUACUUCGAtt-3' 
3'-UaUGAAUGCGACUCAUGAAGCU-5' 
 
         5'-CUUACGCUGAGUACUaUCGAUaU-3' 
3'-ttGAAUGCGACUCAUGAAGCU-5' 
 
             5'-CUUACGCUGAGUACUaUCGAUaU-3' 
3'-UaUGAAUGCGACUCAUGAAGCU-5' 
 






         5'-CUUACGCUGAGUACUUCGAUaU-3' 
3'-ttGAAUGCGACUCAUGAAGCU-5' 
 
            5'-CUUACGCUGAGUACUUCGAUaU-3' 
3'-UaUGAAUGCGACUCAUGAAGCU-5' 
 
































































In the next set of experiments, we examined the hybridization affinity of UaU-modified 
siRNAs that target pGL3.  Including overhangs, there are three potential positions to place a UaU 




the duplexes studied and their respective Tm.  Similar to Table 3-3, siRNAs that contain internal 
UaU modifications (siRNA 9-14) display a degree of thermal destabilization with values that are 
consistent with those obtained for siRNAs that target pGL2.  Furthermore, modifications at the 
3’-overhangs (siRNA 15-17) have minimal effect on overall thermal stability. 
 
 
3.2. Circular Dichroism 
3.2.1. Introduction 
Changes in the three dimensional structure of RNA can be monitored using CD, which 
studies the differential absorbance of circularly polarized light [131]. CD can be used to gauge 
the structure of a double helix because the form of the helix imparts a distinct CD spectra and it 
has been shown that there is no systematic change in this spectra with base composition [132]. 
For instance, it is known that RNA duplex in an A-form helix has a shallow trough at 
approximately 210 nm and a large peak at approximately 262-264 nm and a B-form helix has a 
trough at 220 nm and a peak at 270 nm with approximately the same magnitude. Z-form 
duplexes exhibit a collapsed intensity at the 275 maximum compared to the B-form duplexes 





Figure 3-4: Representative CD spectra for three types of helical structures. A-form helices are 
typical of RNA:RNA duplexes and B-form helices are typical of DNA:DNA duplexes. Figure 
redrawn from reference [124].  
 
Circular dichroism has been tremendously useful for studying the interactions between 
chemically modified oligonucleotides with their target sequences. CD is especially useful in the 
case of backbone-modified oligonucleotides where the chromophore (base) remain unchanged, 
because any change in the molar ellipticity (θ) can be attributed primarily to a conformational 
change in the oligonucleotide or complex, revealing valuable information about the secondary 
structure. 
 
3.2.2. Experimental Procedures 
The RNAs used in this section were shown in Table 3-2, 3-3, and 3-4. CD spectroscopy 
was performed on a Jasco J-815 CD equipped with temperature control. Equimolar amounts of 





NaCl, 10mM Na2HPO4, 1mM EDTA, pH 7) at 90 ºC for 2 minutes and this solution was cooled 
slowly to room temperature. Four hundred microliters of this solution was transferred to a 0.5 
mL quartz cuvette with a one cm path length. CD measurements of each duplex were recorded in 
quadruplicate from 200 to 310 nm at 20 ºC in the sodium phosphate buffer, with a scanning rate 
of 50 nm/min and a 0.2 nm data pitch. Three scans were performed for each sample, averaged, 
and the background was subtracted. 
 
3.2.3. Results and Discussion 
To determine whether the internal amide-bond modification in this study alter the overall 
A-from helical geometry of RNA duplex required for activity [121, 122]. CD was used to assess 
the global conformation of the modified duplex RNAs. For three uracil 18mer oligonucleotides 
(Table 3-2, RNA a, b, and c ), as illustrated in Figure 3-4, the samples were compared with the 
CD spectrum of the unmodified sequence. All four oligonucleotides had negative and positive 
CD bands observed at approximately 210 and 265 nm, respectively, which corresponds to an A-
type duplex. There was a slight difference in crossover point with the chemically modified 
duplex; however, the overall shapes of the spectra are similar, thus, implying that the global 
conformation of the duplex RNAs containing a UaU unit does not alter significantly from wild-
type RNA duplex. Furthermore, the overall shape of the CD curves is consistent with other 





Figure 3-5: CD spectra of RNAs a-c complexed with rA18 in a sodium phosphate buffer (90 mM 
NaCl, 10 mM Na2HPO4, 1 mM EDTA, pH 7). The solution was scanned from 200 to 310 nm at 
20ºC. All scans were performed in quadruplicate and averaged using version 2 of Jasco’s Spectra 
Manager software. 
 
For siRNAs targeting pGL2 and pGL3 vectors, As shown in Figure 3-5, A and B, 
negative and positive CD bands at 209 nm and 260 nm, respectively, which were attributable to 
A-type duplexes, were observed. Although the intensity of the positive and the negative bands of 
these modified siRNAs containing PNA-RNA dimer unit were slightly smaller than that of 
unmodified siRNA, a fact that is usually attributed to a reduction in base stacking [133], the 
shapes of their spectra were similar. These results imply that the global conformation of these 
modified siRNAs containing PNA-RNA dimer unit are not significantly different from that of 





















































Figure 3-6. RNA duplex conformation of all anti-luciferase siRNAs displayed through circular 
dichroism spectroscopy. Duplex siRNAs (~1.7 nmol/duplex) were suspended in 400 µL of a 
sodium phosphate buffer (90 mM NaCl, 10 mM Na2HPO4, 1 mM EDTA, pH 7) and the solution 
was scanned from 200–310 nm at 20 ⁰C. All scans were performed in quadruplicate and 






luciferase siRNAs wt pGL2 and 1–8; (B) Wild-type and modified anti-luciferase siRNAs wt 
pGL3 and 9–17.  
 
3.3. Chapter Summary 
Overall, Tm data support the conclusion that the introduction of one or more UaU 
modification at the internal position leads to destabilization, whereas UaU modifications at the 
3’-overhang observe little change in thermal stability. On the other hand, the RNA duplexes that 
contain the UaU dimer clearly still retain the overall A-from helical geometry. Although 
conformational features alone do not decide the interfering activity, an RNA-like A-type 














Chapter 4: Biological Properties of siRNAs Containing Internal Amide-Bond 
Linkages 
4.1. Investigation of Gene-Silencing Properties of siRNAs Containing Internal 
Amide-Bond Linkages 
4.1.1. Introduction 
In this chapter, we focus on the use of synthetic 21-mer siRNA duplex molecules in 
mammalian cells for transient gene silencing. siRNA molecules are potent effectors of post-
transcriptional gene silencing. Using bioluminescent imaging and a mathematical model of 
siRNA delivery and function, the effects of target-specific siRNA-mediated gene silencing are 
monitored in cells stably expressing the firefly luciferase protein. In a luciferase reporter assay, 
luciferase genes are placed into mammalian cells through transfection. Expression of the 
luciferase reporter gene is then measured to quantify the activity of the regulatory proteins in the 
biological pathway affected by the target element.  
Firefly luciferase is widely used as a reporter for studying gene regulation and function, 
and for pharmaceutical screening [128, 129]. It is a very sensitive genetic reporter due to its high 
sensitivity dynamic range and its natural absence from mammalian cells. The enzyme catalyzes 
ATP-dependent D-luciferin oxidation to oxyluciferin, producing light emission centered at 560 
nm (Figure 4-1). Maximum light output is not achieved until the substrate and co-factors are 
present in large excess. When assayed under these conditions, light emitted from the reaction is 





Figure 4-1: Bioluminescent reaction catalyzed by firefly luciferase. 
 
Renilla Luciferase has been widely used in multiplex transcriptional reporter assays or as 
a normalizing transfection control for firefly luciferase assays [134]. Renilla luciferase, a 
monomeric 36,000 Dalton protein, catalyzes coelenterazine oxidation to produce light (Figure 4-
2) [135]. 
 
Figure 4-2: Bioluminescent reaction catalyzed by Renilla luciferase 
 
In this study, the RNAi-inducing ability of siRNA containing internal amide bond 
linkages was studied using a dual-luciferase assay. The siRNA sequences were designed to target 
firefly luciferase. HeLa cells were co-transfected with the vector (pGL2 or pGL3 and pRLSV40 
luciferase-expressing plasmids) and the indicated the amounts of siRNAs. Both pGL2 and pGL3 
are for SV40 promoter driven firefly Luciferase expression. pRLSV40 is for thymidine kinase 
promoter driven Renilla Luciferase expression. The signals of firefly luciferase were normalized 
to those of the Renilla luciferase. In dual luciferase reporter assays, two luciferase enzymes are 
simultaneously expressed and detected in a single sample. Dual luciferase reporter assays are 




reporter gene and normalizing due to eliminate experimental artifacts. For data normalization 
experiments, firefly reporter gene generally functions as an experimental reporter and the second 
(Renilla reporter gene) as an internal control to account for non-specific experimental variations 
due to operator error or as a result of non-specific effects of biological manipulations or cell 
treatments. Additional experimental variations include: differences in cell plating, differences in 
cell viability or proliferation due to an experimental treatment, edge effects caused by uneven 
environmental conditions in the cell culture incubator, and non-specific effects of the treatment 
compound on the function of the reporter itself. 
In Messere’s work, they showed that the introduction of PNA in the 3’-overhangs in 
either or both strands of siRNA was well tolerated by the RNAi machinery, because all the 
modified siRNAs still mediated efficient gene silencing [4]. Similarly, Iwase et al. reported that 
siRNAs containing the amide-linked RNA segments in the 3’-overhangs in both strands 
effectively inhibited firefly luciferase activity comparable to the unmodified siRNA. These 
results suggest that the amide-linked RNA segments were compatible with the RNAi machinery.  
In our study, through solid-phase RNA phosphoramidite chemistry, we were able to 
control the site-specific location of the PNA monomer by controlling its location within the 
desired RNA strand. In this chapter, the gene-silencing ability of these end and internally amide-
bond modified siRNAs are studied using a dual-luciferase assay. This is the first report that 







4.1.2. Experimental Procedure 
Cell Culture  
In the present study the human epithelial cervix carcinoma cell line HeLa was used. Cells 
were routinely maintained in 25 mL DMEM (Dulbecco’s modified Eagle’s Medium) 
supplemented with 10% fetal bovine serum (FBS) (Perbio), 1% Penicillin-Streptomycin (Sigma) 
at 37 °C in a humidified atmosphere containing 5% CO2. Confluent cells were passaged 
according to the following protocol: Cells were washed twice with PBS, pH 7.4, (Invitrogen) and 
incubated with 2 mL of 0.25% Trypsin (SAFC Bioscience) for 2 minutes at 37°C to detach cells 
from the plastic surfaces. The cell suspension was resuspended in 5 mL of culture medium and 
counted using a haemocytometer. 1,000,000 cells were seeded into new cell culture flask 
containing culture medium.  
For freezing, the trypsinized cells were supplemented with 5 mL culture medium and 
centrifuged for 5 minutes at 12,000 rpm in a centrifuge. The cell pellet was resuspended in 
culture medium. A density of 1,000,000 of cells was transferred to a cryo tube containing 100 µL 
of dimethylsulfoxide followed by adding 300 µL of FBS,  and were slowly cooled down to -
80 °C in a polystyrene box. For long-term storage cells were transferred to liquid nitrogen 
container.  
For thawing, frozen cells were dethawed using warm culture medium, transferred to a 
Falcon tube containing 10 mL of culture medium and centrifuged for 5 minutes at 12,000 rpm to 
remove residual DMSO followed by resuspension in 1 mL of fresh culture medium to remove 
residual DMSO. The cell suspension was transferred to a new 25 mL cell culture flask and 





Transfection of HeLa with lipofectamine 2000  
Prior to transfection, HeLa cells were seeded on 12-well plates (Greiner Bio-One) at a 
density of 10,000 cells per well and incubated at 37 ⁰C with 5 % CO2 in DMEM containing 10% 
FBS. After 24 hr, for each well varying concentrations (8, 80 and 800 pM) of all anti-luciferase 
siRNAs were co-transfected with either 100 ng of pGL2 (Promega) or pGL3 (Promega) and 100 
ng of pRLSV40 luciferase-expressing plasmids using 1µL of Lipofectamine 2000 (Invitrogen) in 
200 µL of Gibco’s Opti-Mem Reduced Serum Medium 1X (Invitrogen) according to the 
manufacturer’s protocol. 
 
Preparation of cells for Luciferase reporter assay 
Twenty-four hours after transfection, cell culture media was removed. Cells were washed 
two times in PBS, lysed for 20 minutes at room temperature in 1xPLB (Passive Lysis Buffer), 
immediately followed by measurement on a Synergy HT (Bio-Tek) plate luminometer. The cell 
lysate was loaded onto white and opaque, 96-well plates (Costar) suitable for luminometric 
measurement. Using the Dual-luciferase Reporter Assay kit (Promega), 30 μL LAR II was first 
added for firefly luciferases activity measurements followed by adding 30 μL Stop&Glow for 
Renilla Luciferase activity measurements. The observed luminescence was proportional to both 
firefly and Renilla luciferase expression, recorded on a luminometer.  
 
Normalization, Interpretation  
Three aliquots of each sample were measured to calculate an average value. To determine 
the efficiency of RNAi constructs, we correlated reporter enzyme activities of transfection of 




luciferase siRNAs. The reporter activity of control transfection (luciferase-expression plasmids) 
was set to 100%. Different transfections were normalized by Renilla luciferase expression and 
standard deviations were calculated from the differences in RNAi efficiency of repeated 
transfections. 
 
Transformation of Plasmid DNA into E. coli Using the Heat Shock Method 
Competent DH5  E. coli cells were taken out from -80 ºC freezer (50 µL aliquots) and 
thawed on ice. 50 ng of circular DNA (Promega) was added into E.coli cells followed by 10 min 
incubation on ice to thaw competent cells. The tube with competent cells and DNA was placed 
into water bath at 42 °C for 45 seconds (heat shock) and then placed back in ice for 2 minutes to 
reduce damage to the E. coli cells. One mL of LB broth (with no antibiotic added) was added and 
the transformed cells were incubated at 37 °C for 1 hr with agitation.  100 µL of the resulting 
culture was spread on warmed agar plates (with Ampicillin added). The cell culture was grown 
overnight at 37 °C. The single colonies for each DNA plasmids were selected about 12-16 hrs 
later. The colonies picked were placed in 5 mL LB broth and 50 µL of Ampillicin, and then 
incubated in the 37 °C shaker overnight.  
 
Mini prep plasmid DNA purification  
We purified DNA plasmids from bacterial cultures (Competent DH5α E. coli) with the 
QIAgen QIAprep Spin Mineprep kit Purification System of Promega according to 
manufacturer’s instruction. In brief, 5 mL of an overnight culture were centrifuged 10 minutes at 
4,180 rpm (Eppendorf Centrifuge) in order to harvest bacterial cells from culture. The pellet was 
resuspended in 250 μL of resuspension solution. The addition of 250 μL of cell lysis solution 




the lysate was again mixed by inverting the tube. After centrifugation at 13000 rpm, the 
supernatant of the lysate was transferred to the QIAprep spin column.  0.75ml of wash solution 
was added. The minicolumn was transferred to a microtube and centrifuged for one minutes at 
full speed (13,000 rpm), to remove residual wash solution. Afterwards the minicolumn was 
transferred to a new collection tube, 50 μL of EB buffer (10mM Tris-Cl, pH 8.5) was added and 
after five minute of incubation, the dissolved plasmid DNA was eluted by one minute of 
centrifugation at 13000 rpm. The purified DNA plasmid was quantified by using a UV 
spectrometer. 
 
4.1.3. Results and Discussion 
The ability of the modified siRNAs to suppress gene expression was studied by a dual-
luciferase assay using pGL2/3 and pRLSV40 plasimids which contained firefly and Renilla 
luciferase genes, respectively. The siRNA sequences were designed to target firefly luciferase. 
HeLa cells were co-transfected with the luciferase plasmids and the indicated amounts of 
siRNAs. The control used in this set of experiment is the luciferase activity given by the cells 
after the 24 hrs transfection with two luciferase plasmids (pGL2/3 and pRLSV40). The signals of 
firefly luciferase were normalized to those of the Renilla luciferase. The final relative luciferase 
signals of each siRNA were normalized to that of the control in each set of experiment.  
Both luciferase vectors (pGL2 and pGL3) carry the coding region for firefly luciferase 
[17]. However, there are differences in the coding sequence from each vector which allows us to 
use two different parent siRNAs. The reason for us to use two different parent siRNA sequences 
is because the most critical issue in developing the chemically modified siRNA is the placement 




have been known to have implications on RNAi activity [54]. In other words, the effect of the 
modifications on the potency of the siRNA was found to be dependent on the position as well as 
the type of modification used. By using two different parent siRNAs, we can expand the scope of 
siRNAs that contain the chemically modified UaU dimer unit which replaces two adjacent 
uridine residues in the wild-type parent sequence to examine their function. The sequences of the 
siRNAs targeting both pGL2 and pGL3 are shown in Table 3-1 
In chapter 3, based on the results of the thermodynamic study (Tm), we learned that in 
general, the introduction of this internal amide bond linkage causes destabilization effect, 
whereas modifications are at the 3’-overhang observe little change in thermal stability. There is a 
correlation between the thermodynamic and activity based on thermodynamic asymmetry in the 
siRNA duplex [45, 136]. In thermodynamic asymmetry rule, the siRNA strand containing the 
thermodynamically less stable 5’-end is preferentially incorporated as the guiding strand of RISC, 
while the non-guiding sense strand of the siRNA duplex is cleaved by Ago 2 and liberated. It has 
been shown that siRNA activity is primarily enhanced by favouring the incorporation of the 
intended antisense strand during RISC complex loading by modulation of siRNA 
thermodynamic asymmetry. In this chapter, we want to explore how our thermally destabilizing 
modification (UaU modification) affects the siRNA potency. 
 The gene-silencing ability of the chemically-modified siRNAs outlined in Table 2-1 was 
tested at 8, 80 and 800 pM within HeLa cells. To gauge efficacy, the mammalian cells were co-
transfected with pGL2 target firefly luciferase plasmid and a non-target Renilla luciferase 
plasmid (pRLSV40). Following transfection, the cells were lysed after 24 hours and luciferase 




As shown in table 3-3, both siRNA 1 and 2 contain the UaU modification near the 3'-end 
of the sense strand, whereas, siRNA 2 has an additional the UaU modification at the 3’-overhang 
of the antisense strand. The potency of both siRNA was relatively limited compared to the wild-
type. This suggests that the modification near the 3’-end of the sense strand is not well tolerated.  
SiRNA 3 contains two internal UaU-modified siRNAs and exhibits the highest degree of thermal 
destabilization. There is no appreciable silencing observed with this siRNA. Compared to siRNA 
1, siRNA 3 contains an internal UaU modification which is place adjacent the Ago 2 cleavage 
site where target mRNA cleavage occurs on the antisense strand which is a less tolerated 
modification. There are several explanations for this region’s particular sensitivity to 
modification. First, Because only one strand of RNA remains in the mature RISC, the antisense 
strand is entirely responsible for silencing activity once the RISC has formed [28]. Thus, it seems 
reasonable that the antisense strand would have more stringent structural requirements than the 
sense strand, which serves essentially as a carrier for the antisense strand. As such, modification 
of the antisense strand had a strong impact on siRNA silencing activity with the most efficient 
antisense strands being only modestly modified [47]. In addition, target mRNA cleavage occurs 
opposite the link between the 10th and 11th nucleotides of the antisense RNA, when counting 
from the 5’-end (in the center of a 21 bp siRNA) [137]. Modifications near this particular  area of 
the antisense strand was found to cause a decrease in RNAi function [52, 138], due to the fact 
that the phosphate groups from this particular area of the antisense strand are involved in key 
points of contact with the RISC protein complex [139].  
siRNAs 4–6 contain the UaU modification in different combinations at the 3’-overhang. 
These siRNAs exhibit potency comparable to wild-type. At certain concentrations (800 pM for 




results indicate that the UaU modification on 3’-overhangs are well tolerated by RNAi machinery 
in the sense strand, in the antisense strand and in both strands of the siRNA and can even 
enhance their potency. This observation is consistent with the several other studies [47, 54, 140]. 
In a recent study reported by a collaboration amongst various European research groups, they 
showed destabilizing modification on the 3’-overhang in the sense strand can be utilized to 
favour antisense strand selection during RISC loading irrespective of the thermodynamic 
asymmetry of the duplex, thus increase siRNA silencing activity [47]. 
Finally, for siRNAs 7 and 8, these RNAs contain the UaU modification adjacent the Ago 
2 cleavage site on the antisense strand. Like siRNA 3, these siRNAs exhibit reduced silencing 
compared to wild-type. However, when a UaU modification is used at the 3’-end of the sense 
strand in combination with the internally-modified UaU antisense strand (siRNA 8), improved 
potency is observed at 80 and 800 pM when compared to siRNAs 3 and 7.  
This gene-silencing data for pGL2 suggests that internal modifications near the 3’-end of 
the sense strand are compatible with the RNAi machinery, however at reduced efficacy 
compared to wild-type. On the other hand, siRNAs functionalized with internal UaU 
modifications at the antisense strand (adjacent the Ago 2 cleavage site on the sense strand) are 
not effective gene-silencing substrates. Furthermore, 3’-UaU overhang modifications on the 
sense strand can offer some increase in potency; however, if the UaU modification is placed on 
the antisense strand and is used with an siRNA that contains a chemically modified sense strand 
(siRNAs 2 and 5), a reduction in potency is observed. This observation of reduced potency with 





Figure 4-3: Reduction in firefly luciferase pGL2 expression related to the potency of amide-
bond modified siRNAs using the Dual-luciferase reporter assay.  The siRNAs were tested at 8, 
80, and 800 pM, with firefly luciferase expression normalized to Renilla luciferase.         
 
In the next set of experiments (Figure 4-4), we examined the efficacy of our siRNAs that 
target pGL3.  Table 3-4 illustrates the duplexes studied and their respective Tm. In general, all 
siRNAs silence in a dose-dependent manner. Starting with siRNA 9 and 10, both of them contain 
the UaU modification near the 5’-end of the sense strand. In both cases, it appears that 
destabilizing the 5’-end of the sense strand led to a decrease in activity at all concentrations 
tested, This is in good agreement with the selection of sense and antisense strand based on 
thermal asymmetry in the siRNA duplex [45, 142]. RISC is preferentially loading the antisense 
strand that has a lower thermostability at the 5’-end. Destabilizing the 5’-end of the sense strand 
could potentially disfavour the incorporation of the antisense strand into the RISC complex, thus, 
reducing the siRNA potency. On the other hand, siRNA 10 exhibits a larger degree of thermal 




SiRNAs 11–14 contain internal UaU modifications near the 3’-end of the sense strand. 
SiRNAs 11 and 13 contain the modification only on the sense strand which is known be more 
tolerant to chemical modifications. Compared to siRNAs 12 and 14, siRNA 11 and 13 are more 
potent. At 80 and 800 pM, siRNA 13 displays potency comparable to wild-type siRNA. SiRNA 
12 exhibits the greatest degree of thermal destabilization in this group. It exhibits a great 
decrease in RNAi function at all concentrations tested. Similarly to the studies with pGL2, the 
presence of a chemically modified substituent at the 3’-overhang of the antisense strand of the 
siRNA may impede its activity when used in combination with an internal UaU modification. 
Finally, the group of siRNAs 15 –17 contain UaU modifications in different combinations 
at the 3’-overhangs of the sense and antisense strand. As described earlier, placing a destabilizing 
modification on the 3’-overhang of the sense strand can enhance the siRNA silencing activity 
which explains why siRNA 15 exhibits silencing comparable to wild-type at 80 and 800 pM. 
SiRNA 16 has a slight loss in potency compared to siRNA 15, perhaps due to the effect of 
modifying the 3’-end of the antisense strand. SiRNA 17 exhibits the lowest potency profile from 
this group at concentrations of 8 and 80 pM. It contains the UaU modification at the 3’-end of the 
antisense strand at which the antisense strand is bound by Ago 2 during RISC loading. 







Figure 4-4: Reduction in firefly luciferase pGL3 expression related to the potency of amide-
bond modified siRNAs using the Dual-luciferase reporter assay.  The siRNAs were tested at 8, 
80, and 800 pM, with firefly luciferase expression normalized to Renilla luciferase. 
 
             
4.2.  Enzymatic Stability of siRNAs containing internal amide-bond linkages 
4.2.1. Introduction 
In order for a cell to protect itself against foreign nucleic acids (i.e. viruses), it produces 
nucleases to enzymatically degrade foreign DNA and RNA. In order for siRNA to get past the 
host defense and to have therapeutic benefits, the siRNAs must be able to withstand degradation 
by exonucleases and endonucleases that catalyze the hydrolysis of phosphodiester bonds. Nature 
RNA is very quickly degraded in cells. The fact that siRNA is double-stranded provides it with 




been found to play a key role in degradation of siRNA [143], and expression levels of them 
inversely correlate with duration of siRNA activity [144]. This and other data suggest that 
increasing the nuclease resistance of siRNAs can prolong their activity.  
Chemical modification is the principal strategy used to improve the nuclease resistance of 
siRNAs. As demonstrated in chapter one, it has been shown that certain backbone modified 
oligonucleotides (e.g., phosphorothioate and boranophosphate linkage) show increased 
enzymatic stability. In the case of the amide-bond backbone modification, Uhlmann and his 
coworkers have shown  that PNA substitutions enhance DNA resistance to serum-derived 
nucleases [80]. Moreover, in both Messere’s and Iwase’s study, the introduction of a amide bond 
modification on only the 3’-overhanging in both or either strands of siRNA leads to significant 
resistance against serum-derived nucleases [4, 5]. 
In this section, we examined whether the introduction of PNAs monomer in the 3’-end 
could lead to a siRNA that is more stable in the extracellular environment. We used fetal bovine 
serum as models for a 3’-exonuclease and an endonuclease.  
 
4.2.2. Experimental Procedure  
Unmodified and modified siRNAs were incubated in 13.5% fetal bovine serum at 37 °C 
for various times periods.  At different time points (0.5, 1.5, 3 and 5 hrs), aliquots of each siRNA 
were incubated with fetal bovine serum at 37 °C. After 5 hrs, samples were subjected to 
electrophoresis in 20% polyacrilamide-Tris-Borate-EDTA (TBE) under non-denaturing 




4.2.3. Results and Discussion 
Because of the rapid degradation of unmodified siRNAs in serum, it is clear that some 
form of protection will be required for systemic delivery. This can be achieved by chemical 
modification of the siRNA itself. Several studies have shown that chemically modified siRNAs 
can be highly resistant to nuclease degradation yet still function as effectors of RNA interference 
[145, 146].  
In our study, the stability of siRNAs that have the PNA-RNA dimer on the 3’-overhangs 
in both or either strands in fetal bovine serum which contains heat-stable nucleases, was 
examined. Two sets of siRNAs (4, 5 &6 for pGL2 and 15, 16 &17 for pGL3) (Table 3-5) were 
incubated in water containing 13.5% bovine serum and analyzed by 20% native PAGE under 
denaturing condition. Nuclease stability can be judged from the relative intensity of the bands at 
each time point, with degradation indicated by the disappearance of the bands over time. As 
shown in Figure 3-5, A, the unmodified siRNA for pGL2 was completely digested after 1.5 hrs 
incubation. A similar degradation profile was observed for the unmodified siRNA for pGL3 
(Figure 3-6, A). On the other hand, siRNA 4, 5, and 6 were more stable that unmodified siRNA 
(Figure 3-5, B, C, and D), because after 5 hrs of incubation an electrophoretic band 
corresponding to the intact duplex was still evident. In the case of pGL3, siRNAs 16 and 17 
(Figure 3-6, C and D) were gradually digested after 3 hrs. SiRNA 15 (Figure 3-6, B) showed a 
significant improvement in stability, because a band corresponding to the intact duplex was still 
evident even after 5 hrs of incubation. Overall, these results imply that the introduction of PNA-
RNA dimer at the 3’-end of the siRNA where the exonuclease cleaves the terminal nucleotide, 





















    
    5'-CGUACGCGGAAUACUUCGAtt-3' 
3'-ttGCAUGCGCCUUAUGAAGCU-5' 
 
         5'- CGUACGCGGAAUACUUCGAUaU-3' 
3'- ttGCAUGCGCCUUAUGAAGCU-5' 
 
              5'-CGUACGCGGAAUACUUCGAUaU-3' 
 3'-UaUGCAUGCGCCUUAUGAAGCU-5' 
 














    5'- CUUACGCUGAGUACUUCGAtt-3' 
3'- ttGAAUGCGACUCAUGAAGCU-5' 
 
        5'-CUUACGCUGAGUACUUCGAUaU-3' 
3'-ttGAAUGCGACUCAUGAAGCU-5' 
 
                 5'-CUUACGCUGAGUACUUCGAUaU-3' 
    3'-UaUGAAUGCGACUCAUGAAGCU-5' 
 
             5'-CUUACGCUGAGUACUUCGAtt-3' 

















   
 
 
   
Figure 4-5: Native PAGE gel displaying degradation patterns of 3’-modified pGL2 siRNAs in a 
time-dependent nuclease stability assay. Samples were incubated at 37 ⁰C in 13.5% FBS before 
they were resolved on 20% SDS-PAGE.  Bands were stained with Gel Red (3X). (A) 
Degradation pattern of wt pGL2 anti-luciferase siRNA; (B) Degradation pattern of siRNA 4; (C) 
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Figure 4-6: Native PAGE gel displaying degradation patterns of 3’-modified pGL3 siRNAs in a 
time-dependent nuclease stability assay. Samples were incubated at 37 ⁰C in 13.5% FBS before 
they were resolved on 20% SDS-PAGE.  Bands were stained with Gel Red (3X). (A) 
Degradation pattern of wt pGL3 anti-luciferase siRNA; (B) Degradation pattern of siRNA 15; 
(C) Degradation pattern of siRNA 17; (D) Degradation pattern of siRNA 16.  
 
A question that remains is whether or not nuclease stabilization also affects the kinetics 
of siRNA-mediated gene silencing. If enhanced nuclease stability allows the siRNAs to remain 
intact longer inside the cell, it might lead to an increase in the duration of gene inhibition, which 
siRNA 15 incubation with FBS (hr) 
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siRNA wt pGL3 incubation with FBS (hr) 






still needs to be proven by further experiment. An ideal modified siRNA design would be 
expected to enhance both the magnitude and duration of gene silencing. It has been reported that 
when transfected into cells, modified siRNA was capable of maintaining the knockdown effect 
for a longer period as compared to unmodified siRNA [53, 122].  
Our observations on cell-based luciferase assays indicate that these 3’-end modified 
siRNAs do not provide considerable advantages in vitro with regard to the magnitude of gene 
silencing. In fact, these modified siRNAs are more costly to produce and frequently show 
decreased activity relative to unmodified siRNAs of the same sequence. However, the added 
costs and the potential for decreased activity of nuclease-stabilized siRNAs may be outweighed 
by other factors for in vivo applications. Recent reports have indicated that chemical 
modifications can modulate the immunostimulatory properties of siRNAs [147]. Moreover, 
chemical modifications to confer added nuclease stability can increase the bioavailability of an 
injected siRNA species by protecting it from the rapid nuclease degradation that occurs with 
unmodified siRNAs. If siRNAs are injected locally, as in intratumoral or intramuscular injection, 
the added nuclease stability may increase the time during which siRNAs can be internalized by 
the target cells. 
 
4.3. Chapter summary 
In this chapter, we evaluate siRNA that contain internal amide bond linkages to establish 
novel RNAi substrates for gene-silencing activity in mammalian cells and their nuclease stability. 
We showed the compatibility of utilizing a neutral amide-bond backbone within siRNAs. 
Specifically, the internal backbone amide-bond is compatible within the RNAi machinery when 




toleration of sense strand to chemical modification in comparison to the antisense strand that is 
incorporated into RISC and mediate the binding with target mRNA and mRNA cleavage. In 
addition, the UaU unit is compatible as a 3’-overhanging unit. However, when the UaU unit is 
place adjacent the Ago 2 cleavage site on the antisense strand, poor efficacy is observed. 
Nuclease stability assays showed that in general, the siRNAs that contain 3’-UaU overhangs have 
increased stability compared to wild-type siRNAs, which can potentially lead to a prolonged 




Chapter 5: Conclusion and Future Work 
The end goal of the synthesis and characterization of modified RNA is to extend the 
biological and pharmacokinetic properties of RNA as a therapeutic tool. The work presented in 
this dissertation encompasses the synthesis, chemical and biological characterization, and in vivo 
applications of siRNAs that contain internal amide-bond linkages. We were able to use solid 
phase RNA phosphoramidite chemistry to control the site-specific location of the UaU 
modification through the desired RNA strand. The secondary structure of the internal amide-
bond modified siRNAs all exhibit the standard A-form helix which is required for their gene-
silencing activity [122]. However, it is recommended that these experiments be followed up with 
NMR of modified siRNA to absolutely determine the configuration. Crystallography may also be 
helpful in determination of the secondary structure. 
The thermodynamic profile tells us that in general, internal amide-bond modifications 
display a degree of thermal destabilization, whereas UaU modifications at the 3’-overhang 
observe little change in thermal stability. Overall, this chemical modification within the 
backbone of the oligonucleotide causes a small loss in binding affinity.  
The ability of to silence a gene using was tested in a human cancer line. We demonstrate 
that the internal backbone amide-bond is compatible within the RNAi machinery specifically 
when placed within the sense strand of the double-stranded siRNA. Lastly, based on the results 
given by the nuclease stability assays, the 3’-end modified siRNA proved to be more stable to 
hydrolysis by exonucleases. 
Our results provide a basis for the further development of synthetic amide-bond linked 
siRNA molecules with improved properties, including higher resistance to enzymatic 




technology and broaden the vision of translating the technology into a drug platform. Moreover, 
these molecules represent a further tool for insights into the future studies  investigating on RNA 
recognition by siRNA machinery. 
A large amount of work remains to be done on this type of backbone modification within 
RNAi machinery. Most importantly, we would like to further expand the scope of these internal 
amide-bond modified siRNAs within the biological system using endogenous gene target, such 
as house-keeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or genes involved 
in disease.  
Diseases that are characterized by overexpressed or inappropriate expression of specific 
genes, or genes that are expressed by invading microorganisms, are candidates for gene-silencing 
therapies.  Malignant diseases such as cancer, in particular, are attractive candidates for this 
therapeutic approach if no other reason than that conventional cancer therapies are highly toxic. 
In this section, two potential gene targets will be listed. B-cell lymphoma protein 2 (BCL2) is an 
important apoptosis inhibitor to regulate programmed cell death in oncology and its 
overexpression has been implicated in the pathogenesis of some lymphomas [148]. Targeting 
BCL2 is a promising example of triggering apoptosis in tumour cells. Laboratory studies have 
shown convincingly that exposing cells to ONDs targeted to BCL2 will specifically decrease the 
amount of targeted mRNA and protein. For this reason, there is a great deal of interest in 
targeting BCL2 for therapeutic purpose [149]. Protein kinase C (PKC) comprises a family of 
biochemically and functionally distinct phospholipid-dependent, cytoplasmic serine/threonine 
kinases. These proteins have a crucial role in transducing the signals that regulate cell 
proliferation and differentiation. PKC is overexpressed in several tumours, and antisense 




two studies that used identical 20-mer phosphorothioate ODN against PKC have been published 
[150, 152]. The ODN was well tolerated. As a part of future direction, we would like to look into 
whether our internal amide bond modified siRNAs will have the same gene silencing ability as 
illustrated in other studies when used to target BCL2 and PKC.   
Secondly, we would like to examine the nuclease stability against endonucleases using 
siRNAs that contain the UaU modification in the internal Watson-Crick region. In addition, we 
would like to know whether increased stability seen with modified siRNAs can prolonged the 
duration of RNAi in vivo because the duration of gene inhibition by siRNA is a primary factor in 
determining the dosing schedules required to achieve therapeutic effects. We could transfect 
HeLa cells with unmodified and modified siRNAs and the luciferase activity of the cells will be 
monitored over time through live-cell bioluminescent imaging. This will reveal the impact of 
modified siRNA nuclease stability on the kinetics of siRNA-mediated gene silencing. 
 Lastly, due to the fact that the ability of the siRNA to silence gene expression is 
predicated on its capacity to cross the cell membrane and gain access to the RISC machinery in 
the cytoplasm, we would also like to determine the lipophilicity of modified siRNAs to facilitate 
cellular delivery through passive transport across the cell membrane. An efficient method 
involves utilizing radiolabeled oligonucleotides to measure the partitioning between 1-octanol 
and aqueous phases[153].  
In conclusion, this is the first report that involves amide-bonds as phosphate backbone 
replacements within the internal regions of siRNAs and thus opens the future possibility for 
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